ࡱ> W }Sbjbj u8>>""""""""8##l"mM)M)c)c)y)+O,<, lllllll$tqtl",+"+,,l""c)y)"mw;w;w;, "8c)"y)lw;,lw;w;fd"ujy)w{"=8gDlm0mh`v=8:vujujv"j,,w;,,,,,llw;,,,m,,,,v,,,,,,,,,> G!: APPROVED PRODUCT INFORMATION OLMETEC( (olmesartan medoxomil) NAME OF THE MEDICINE OLMETEC (olmesartan medoxomil), a prodrug, is hydrolyzed to olmesartan during absorption from the gastrointestinal tract. Olmesartan is a selective AT1 subtype angiotensin II receptor antagonist. Olmesartan medoxomil (CAS no. 144689-63-4) is described chemically as 2,3-dihydroxy-2-butenyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[p-(o-1H-tetrazol-5-ylphenyl)benzyl] imidazole-5-carboxylate, cyclic 2,3-carbonate. Its empirical formula is C29H30N6O6 and its structural formula is: DESCRIPTION Olmesartan medoxomil is a white to light yellowish-white powder or crystalline powder with a molecular weight of 558.59. It is practically insoluble in water and sparingly soluble in methanol. OLMETEC is available for oral use as film-coated tablets containing 10mg, 20mg, or 40mg olmesartan medoxomil. OLMETEC tablets also contain the following inactive ingredients: microcrystalline cellulose, low-substituted hydroxypropylcellulose, lactose, hydroxypropylcellulose, magnesium stearate, and Opadry OY-S-38956 that contains titanium dioxide, talc, and hydroxypropylmethylcellulose. OLMETEC extemporaneous suspension contains additional inactive ingredients: purified water, Ora-Sweet (syrup vehicle) and Ora-Plus (suspending vehicle). Ora-Sweet contains citric acid, flavouring, glycerine, methylparaben, potassium sorbate, sodium phosphate, sorbitol, sucrose, and purified water. Ora-Plus contains calcium sulphate, carrageenan, citric acid, dimethicone antifoam emulsion, methylparaben, microcrystalline cellulose, sodium carboxymethylcellulose, potassium sorbate, sodium phosphate monobasic, trisodium phosphate, xanthan gum, and purified water. PHARMACOLOGY Pharmacodynamics Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation and renal reabsorption of sodium. Olmesartan medoxomil is an orally active angiotensin II receptor (type AT1) antagonist. It has more than a 12,500-fold greater affinity for the AT1 receptor than for the AT2 receptor. It is expected to block all actions of angiotensin II mediated by the AT1 receptor, regardless of the source or route of synthesis of angiotensin II. The selective antagonism of the angiotensin II (AT1) receptors results in increases in plasma renin levels and angiotensin I and II concentrations, and some decrease in plasma aldosterone concentrations. Angiotensin II plays a significant role in the pathophysiology of hypertension via the type1 (AT1) receptor. In hypertension, olmesartan medoxomil causes a dose-dependent, long-lasting reduction in arterial blood pressure. There has been no evidence of first-dose hypotension, of tachyphylaxis during long-term treatment, or of rebound hypertension after cessation of therapy. Once daily dosing with olmesartan medoxomil provides an effective and smooth reduction in blood pressure over the 24-hour dose interval. Once daily dosing produced similar decreases in blood pressure as twice daily dosing at the same total daily dose. With continuous treatment, maximum reductions in blood pressure are achieved by 8weeks after the initiation of therapy, although a substantial proportion of the blood pressure lowering effect is already observed after 2weeks of treatment. When used together with hydrochlorothiazide, the reduction in blood pressure is additive and coadministration is well tolerated. The effect of olmesartan on mortality and morbidity is not yet known. Pharmacokinetics Absorption Olmesartan medoxomil is a prodrug. It is rapidly converted to the pharmacologically active metabolite, olmesartan, by esterases in the gut mucosa and in portal blood during absorption from the gastrointestinaltract. No intact olmesartan medoxomil or intact side chain medoxomil moiety have been detected in plasma or excreta. The mean absolute bioavailability of olmesartan from a tablet formulation was 25.6%. The mean peak plasma concentration (Cmax) of olmesartan is reached within about 2hours after oral dosing with olmesartan medoxomil, and olmesartan plasma concentrations increase approximately linearly with increasing single oral doses up to about 80mg. Food has minimal effect on the bioavailability of olmesartan and therefore olmesartan medoxomil may be administered with or without food. Distribution The mean volume of distribution after intravenous dosing is in the range of 1629litres. Olmesartan is highly bound to plasma proteins (99.7%), but the potential for clinically significant protein binding displacement interactions between olmesartan and other highly bound coadministered drugs is low (as confirmed by the lack of a clinically significant interaction between olmesartan medoxomil and warfarin). The binding of olmesartan to blood cells is negligible. In rats, olmesartan crossed the blood-brain barrier poorly, if at all. Olmesartan crossed the placental barrier in rats and was distributed to the foetus. Olmesartan was distributed to milk at low levels in rats. Metabolism Following the rapid and complete conversion of olmesartan medoxomil to olmesartan during absorption, there is virtually no further metabolism of olmesartan. Elimination Total plasma clearance was typically 1.3L/h (CV, 19%) and was relatively slow compared with hepatic blood flow (approximately 90L/h). Approximately 30% to 50% of the systemically absorbed drug is excreted in the urine whilst the remainder is excreted in faeces (via the bile). The terminal elimination half-life of olmesartan varied between 10 and 15hours after multiple oral dosing. Steady state was reached after the first few doses and no further accumulation was evident after 14days of repeated dosing. Renal clearance was approximately 0.50.7L/h and was independent of dose. Pharmacokinetics in special populations Elderly In hypertensive patients, the AUC at steady state was increased by approximately 33% in elderly patients (6575years old) and by approximately 31% (adjusted for gender and body mass index) in very elderly patients ((75years old) compared with the younger age group. Paediatric The single-dose pharmacokinetics of olmesartan was investigated in an open-label study in paediatric hypertensive patients aged 1 to 16 years. Refer to Table 1 for a summary of PK parameters. The clearance of olmesartan in paediatric patients was similar to that in adult patients when adjusted by body weight. There are, however, very limited data on the pharmacokinetics of olmesartan in children less than 6years (see PRECAUTIONS, Paediatric Use). Table 1. Mean plasma pharmacokinetic parameters of olmesartan in paediatric hypertension patients1 Parameter; mean (SD)6-12 Year Age Group (n=10)13-16 Year Age Group (n=10)Cmax (ng/mL)1227 (451)895 (262)AUC0-t (ng/mL*hr)7874 (2913)5851 (2083)AUC0-" (ng/mL*hr)7988 (2913)5982 (2130)Tmax (hr)2.8 (1.3)2.5 (1.1)t1/2 (hr)8.4 (2.4)9.1 (1.9)CL/F (L/hr)4.3 (1.9)6.1 (2.6)1 Sample size insufficient to support calculation of summary statistics in 2-5 year age group (n=4)Gender Minor differences were observed in the pharmacokinetics of olmesartan in women compared with men. AUC and Cmax were 1015% higher in women than in men. Renal impairment In patients with renal insufficiency, serum concentrations of olmesartan were elevated compared with subjects with normal renal function. After repeated dosing, the AUC was approximately tripled in patients with severe renal impairment (creatinine clearance <30mL/min). The pharmacokinetics of olmesartan in patients undergoing haemodialysis has not been studied. Hepatic impairment Mean olmesartan AUC after single oral administration to patients with moderate hepatic impairment (Child-Pugh score 7-9) was increased by about 48% compared with healthy controls (total group), or by about 60% when compared with matched controls only. Following repeated dosing, a similar increase in olmesartan mean AUC was observed in patients with moderate hepatic impairment (Child-Pugh score 7-9) when compared with matched healthy controls. Olmesartan mean Cmax values were similar in hepatically-impaired and healthy subjects. Olmesartan medoxomil has not been evaluated in patients with severe hepatic impairment (Child-Pugh score 10-15). CLINICAL TRIALS The antihypertensive effects of OLMETEC have been demonstrated in seven placebo-controlled studies at doses ranging from 2.5 to 80mg for 6 to 12weeks. Approximately 2,800 patients with essential hypertension were studied. The blood pressure lowering effect of OLMETEC tended to increase with time and to increase with dose up to the 40mg dose (refer Table2). OLMETEC 10mg (n=521), 20mg (n=513), and 40mg (n=195) once daily produced statistically significant reductions in peak and trough blood pressure compared with placebo (n=543) at every time point from Week 2 to Week 12 (sSBP p<0.001 and sDBP p<0.001). Table 2. Absolute reduction in mean systolic and diastolic BP1 (mmHg) (placebo-controlled studies) Study (number of patients)Placebo (n=543)10 mg (n=521)20 mg (n=513)40 mg (n=195)Time pointSE-866/06 (n=76)-2.1/-3.2-8.0/-7.16 weeks866-204 (n=186)0.0/-1.4-12.8/-10.68 weeks866-305 (n=517)-2.1/-4.1-14.6/-12.6-13.1/-11.8-17.3/-12.68 weeks866-3062 (n=343)-4.6/-7.0-10.3/-8.3-13.7/-9.28 weeksSE-866/09 (n=790)-9.1/-9.5-17.1/-12.9-18.4/-14.1-20.6/-15.512 weeksSE-866/10 (n=600)-11.2/-10.2-19.1/-15.9-21.0/-16.812 weeksSE-866/11 (n=287)-4.0/-5.5-13.2/-12.212 weeks1Seated cuff blood pressure measurements; 2This was a dose-titration studyData above from seven placebo-controlled studies also confirm that the blood pressure lowering effect was maintained throughout the 24-hour period with OLMETEC once daily, with trough-to-peak ratios for systolic and diastolic response between 60 and 80%. In a 4-month, open-label, extension study, all patients received 20mg olmesartan medoxomil, which was titrated to 40mg as required. If sitting diastolic blood pressure (sDBP) remained uncontrolled, hydrochlorothiazide 12.525mg was then added. By Week16, the majority of patients remained on 20mg olmesartan medoxomil therapy (56.8%). Mean blood pressures generally continued to decrease in each treatment group from Week 4 to Week 16, as expected from the study design, which allowed treatment to be individually tailored to achieve blood pressure control (refer Table 3). Table 3. Mean systolic and diastolic BP1 (mmHg) values (open-label study) Time pointTotal number of patientsSystolic/diastolic BP (number of patients)20 mg OM40 mg OM40 mg OM + 12.5 mg HCTZ40 mg OM + 25 mg HCTZWeek 4n=399142.6/91.8 (n=379)155.8/100.8 (n=17)155.0/95.5 (n=2)146.0/101.0 (n=1)Week 8n=389137.1/88.3 (n=273)151.5/97.2 (n=93)150.9/97.1 (n=19)144.3/96.5 (n=4)Week 12n=381135.1/86.1 (n=228)146.0/93.2 (n=84)147.4/93.9 (n=58)141.8/91.3 (n=11)Week 16n=366133.8/85.7 (n=208)142.6/90.7 (n=68)142.2/92.8 (n=63)150.2/95.6 (n=27)1Seated cuff blood pressure measurements; Abbreviations: OM olmesartan medoxomil; HCTZ - hydrochlorothiazideThe blood pressure lowering effect of OLMETEC, with and without hydrochlorothiazide, was maintained in patients treated for up to 1-year. There was no evidence of tachyphylaxis during long-term treatment with OLMETEC or rebound effect following abrupt withdrawal of olmesartan medoxomil after 1-year of treatment. The antihypertensive effect of OLMETEC was similar in men and women and in patients older and younger than 65years. The effect was smaller in black patients (usually a low-renin population), as has been seen with other ACE inhibitors, angiotensin receptor blockers and beta-blockers. OLMETEC had an additional blood pressure lowering effect when added to hydrochlorothiazide. Use in elderly The antihypertensive effects of OLMETEC were investigated in a randomised, double-blind, parallel group with losartan in elderly patients (65 years or older; olmesartan n=251 whom 69 were >75 years; losartan n=130 whom 48 were >75 years) with essential hypertension for 52 weeks. Patients were initiated on a starting dose of 20mg OLMETEC and if required, titrated to 40mg after 4 weeks. If after 4 weeks on 40mg OLMETEC target blood pressure was not achieved then hydrochlorothiazide was added. The results obtained for those on OLMETEC were similar to those in the losartan group. Paediatric use The antihypertensive effect of OLMETEC once daily was evaluated in a randomised, double-blind study involving 361 hypertensive paediatric patients (1-5 years n=59, 6-16 years n=302). Renal and urinary disorders with / without obesity were the most common underlying causes of hypertension in these patients enrolled in this study. Refer to Table 4 for a summary of the baseline demographic characteristics of study participants. Table 4. Summary demographic and baseline characteristics Parameter; mean (SD)1-5 Year Age Group (n=60)6-16 Year Age Group (n=302)Age (years)3.4 (1.45)12.3 (2.85)Height (cm)98.3 (12.92)1154.6 (17.79)Weight (kg)16.9 (6.61)171.1 (36.72)Parameter; n (%)Race2White27 (45.0)119 (39.4)Black/African heritage7 (11.7)147 (48.7)Asian21 (35.0)19 (6.3)Hawaiian0 (0.0)1 (0.3)Other5 (8.3)26 (8.6)Male34 (56.7)179 (59.3)Primary Hypertension20 (33.3)225 (74.5)Familial Hypertension17 (28.3)188 (62.3)1n=59 2Patients were allowed to check more than one raceThe study included three periods: a 3 week double-blind, randomised, dose-response period for patients aged 6-16 years or, for patients aged 1-5 years, an open-label dose period; up to 2week double-blind, randomised, placebo-controlled withdrawal period; and a 46 week open-label safety and efficacy period. The primary endpoints were the dose response in systolic blood pressure or in diastolic blood pressure for subjects 6 to 16 years of age at the end of this period. This study was not a clinical outcome study. In the dose-response period, patients aged 6-16 years were randomised to receive either low or high dose of OLMETEC based on their weight. Patients weighing 20 to <35kg received 2.5 mg (low) or 20 mg (high); those weighing e" 35 kg, received 5 mg (low) or 40mg (high). Patients aged 1-5 years who weighed e" 5 kg received a dose of 0.3 mg/kg. At the end of this period, OLMETEC reduced both systolic and diastolic blood pressure in a dose-dependent manner. In patients aged 6-16 years the low and high doses of OLMETEC significantly reduced systolic blood pressure by 6.63 and 11.87 mmHg from the baseline, respectively,. Patients aged 1-5 years of age had a clinically, and a statistically significant change from baseline reduction in systolic blood pressure of 13.31 mmHg. In the placebo-controlled withdrawal period, patients who continued on OLMETEC had smaller increases in their systolic and diastolic blood pressure compared to patients switched to placebo. The difference between placebo and OLMETEC was statistically significant in patients aged 6-16 years, but was not statistically significant in patients aged 1-5 years. Refer to Table 5 for a summary of the mean change in SeSBP and SeSDP for both groups during the open-label (1-5 year age group)/double-blind (6-16 year age group) and placebocontrolled withdrawal periods of the study. Table 5. Summary of mean change in SeSBP and SeSDP (mmHg) during open-label (1-50 year age group)/double-blind (6-16 year age group) period and placebo-controlled withdrawal period 1-5 Year Age GroupSeSBPSeSDPBaseline BP1 Mean (SD)Change from baseline Mean (SD)Baseline BP1 Mean (SD)Change from baseline Mean (SD)Open-label periodOLMETEC (n=59)115.4 (8.62)-13.31 (10.94)72.6 (8.80)-10.42 (9.78)Placebo-controlled withdrawal periodOLMETEC (n=29)101.8 (11.87)1.36 (8.99)60.9 (9.16)0.31 (8.56)Placebo (n=28)101.4 (10.09)4.95 (8.57)61.9 (8.56)3.77 (7.20)6-16 Year Age GroupSeSBPSeSDPBaseline BP1 Mean (SD)Change from baseline Mean (SD)Baseline BP1 Mean (SD)Change from baseline Mean (SD)Double-blind periodLow dose OLMETEC (n=150)130.4 (9.09)-6.63 (10.17)78.6 (8.53)-4.76 (8.39)High dose OLMETEC (n=150)129.8 (8.98)-11.87 (9.84)77.4 (7.78)-8.78 (9.22)Placebo-controlled withdrawal periodOLMETEC (n=145)121.5 (12.66)0.77 (9.45)71.3 (9.70)0.85 (7.79)Placebo (n=141)120.2 (13.00)4.50 (9.75)70.8 (10.42)3.99 (9.63)1Baseline at start of study periodAt the end of the open-label efficacy and safety period, compared to baseline, the mean systolic and diastolic blood pressure were reduced at all visits for all patient age groups. However data in children 1-5 years are limited due to small numbers of patients enrolled in the clinical studies. Overall the clinical trials were unable to demonstrate that OLMETEC was significantly better than placebo in reducing blood pressure in children 1-5 years of age. INDICATIONS OLMETEC is indicated for the treatment of hypertension. CONTRAINDICATIONS OLMETEC is contraindicated in: Patients who are hypersensitive to either olmesartan medoxomil or any component of this medication. Pregnancy (see PRECAUTIONS, Use in pregnancy). Patients with severe renal impairment (creatinine clearance <30mL/min) (see PRECAUTIONS, Renal impairment) Patients with severe hepatic impairment (Child-Pugh score 10-15) or biliary obstruction (see PRECAUTIONS, Hepatic impairment) PRECAUTIONS Intravascular volume depletion Symptomatic hypotension, especially after the first dose, may occur in patients who are volume and/or sodium depleted by vigorous diuretic therapy, dietary salt restriction, diarrhoea or vomiting. Such conditions should be corrected before the administration of olmesartan medoxomil. Other conditions with stimulation of the renin-angiotensin-aldosterone system In patients whose vascular tone and renal function depend predominantly on the activity of the renin-angiotensin-aldosterone system (e.g. patients with severe congestive heart failure or underlying renal disease, including renal artery stenosis), treatment with ACE inhibitors and angiotensin receptor antagonists has been associated with acute hypotension, azotaemia, oliguria or, rarely with acute renal failure and/or death. The possibility of similar effects cannot be excluded with olmesartan medoxomil. Renovascular hypertension There is an increased risk of severe hypotension and renal insufficiency when patients with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney are treated with drugs that affect the renin-angiotensin-aldosterone system. Renal impairment and kidney transplantation When olmesartan medoxomil is used in patients with impaired renal function, periodic monitoring of serum potassium and creatinine levels is recommended. Use of OLMETEC is not recommended in patients with severe renal impairment (creatinine clearance <30mL/min, eGFR <30mL/min/1.73m2) (see DOSAGE AND ADMINISTRATION). There is no experience of the administration of OLMETEC in patients with a recent kidney transplant or in patients with end-stage renal impairment (i.e. creatinine clearance <12mL/min, eGFR <15mL/min/1.73m2). There are no data on the use of olmesartan in children with eGFR less than 25mL/min/1.73m2. Hepatic impairment There is no experience in patients with severe hepatic impairment (Child-Pugh score 10-15) and therefore use of OLMETEC in this patient group is not recommended (see DOSAGE AND ADMINISTRATION). Hyperkalaemia As with other angiotensin receptor antagonists and ACE inhibitors, hyperkalaemia may occur during treatment with OLMETEC, especially in the presence of renal impairment and/or heart failure. Close monitoring of serum potassium levels in at risk patients is recommended. Lithium As with other angiotensin receptor antagonists, the combination of lithium and OLMETEC is not recommended (see Interactions with other medicines). Aortic or mitral valve stenosis; obstructive hypertrophic cardiomyopathy As with other vasodilators, special caution is indicated in patients suffering from aortic or mitral valve stenosis, or obstructive hypertrophic cardiomyopathy. Primary aldosteronism Patients with primary aldosteronism generally will not respond to antihypertensive drugs acting through inhibition of the renin-angiotensin system. Therefore, the use of OLMETEC is not recommended in such patients. Ethnic differences As with all other angiotensin receptor antagonists, the blood pressure lowering effect of OLMETEC is somewhat less in black patients than in non-black patients, possibly because of a higher prevalence of low-renin status in the black hypertensive population. Concomitant use of ACE inhibitors or angiotensin receptor antagonists and anti-inflammatory drugs and thiazide diuretics The use of ACE-inhibitors or angiotensin receptor antagonists, and an anti-inflammatory drug (NSAID or COX-2 inhibitor), and a thiazide diuretic at the same time increases the risk of renal impairment. This includes use with fixed-combination products containing more than one class of drug. Concomitant use of all three classes of these medications should be accompanied by increased monitoring of serum creatinine, particularly at the institution of the treatment. The concomitant use of drugs from these three classes should be used with caution particularly in elderly patients or those with pre-existing renal impairment. Other As with any antihypertensive agent, excessive blood pressure decrease in patients with ischaemic heart disease or ischaemic cerebrovascular disease could result in a myocardial infarction or stroke. Effects on fertility Fertility of rats was unaffected by administration of olmesartan medoxomil at dose levels as high as 1,000mg/kg/day (relative plasma exposure of 7-8times that anticipated at the MRHD based on AUC) in a study in which dosing was begun 2 (female) or 9 (male) weeks prior to mating. Use in pregnancy (Category D) Drugs that act directly on the renin-angiotensin system can cause foetal and neonatal morbidity and death when administered to pregnant women. Several dozen cases have been reported in the world literature of patients who were taking ACE inhibitors. When pregnancy is detected, OLMETEC should be discontinued as soon as possible. The use of drugs that act directly on the renin-angiotensin system during the second and third trimesters of pregnancy has been associated with foetal and neonatal injury, including hypotension, neonatal skull hypoplasia, anuria, reversible or irreversible renal failure and death. Oligohydramnios has also been reported, presumably resulting from decreased foetal function; oligohydramnios in this setting has been associated with foetal limb contractures, craniofacial deformation and hypoplastic lung development. Prematurity, intrauterine growth retardation and patent ductus arteriosus have also been reported, although it is not clear whether these occurrences were due to exposure to the drug. These adverse effects do not appear to have resulted from intrauterine drug exposure that has been limited to the first trimester. Mothers whose embryos and foetuses are exposed to an angiotensin receptor antagonist only during the first trimester should be so informed. Nonetheless, when patients become pregnant, physicians should have the patient discontinue the use of OLMETEC as soon as possible. Rarely (probably less often than once in every thousand pregnancies), no alternative to a drug acting on the renin-angiotensin system will be found. In these rare cases, the mothers should be apprised of the potential hazards to their foetuses and serial ultrasound examinations should be performed to assess the intra-amniotic environment. If oligohydramnios is observed, OLMETEC should be discontinued unless it is considered life-saving for the mother. Contraction stress testing (CST), a nonstress test (NST) or biophysical profiling (BPP) may be appropriate, depending upon the week of pregnancy. Patients and physicians should be aware, however, that oligohydramnios may not appear until after the foetus has sustained irreversible injury. Infants with histories of in utero exposure to an angiotensin receptor antagonist should be closely observed for hypotension, oliguria and hyperkalaemia. If oliguria occurs, attention should be directed toward support of blood pressure and renal perfusion. Exchange transfusion or dialysis may be required as means of reversing hypotension and/or substituting for disordered renal function. There is no clinical experience with the use of OLMETEC in pregnant women. No teratogenic effects were observed when olmesartan medoxomil was administered to pregnant rats at oral doses up to 1,000mg/kg/day (7times clinical exposure to olmesartan at MRHD based on AUC) or pregnant rabbits at oral doses up to 1mg/kg/day (half the MRHD on a mg/m2 basis; higher doses could not be evaluated for effects on foetal development as they were lethal to the does). In rats, significant decreases in pup birth weight and weight gain were observed at doses (1.6mg/kg/day, and delays in developmental milestones (delayed separation of ear auricula, eruption of lower incisors, appearance of abdominal hair, descent of testes, and separation of eyelids) and dose-dependent increases in the incidence of dilation of the renal pelvis were observed at doses (8mg/kg/day. The no observed effect dose for developmental toxicity in rats is 0.3mg/kg/day, about one-tenth the MRHD of 40mg/day. Use in lactation It is not known whether olmesartan is excreted in human milk, but olmesartan is secreted at low concentration in the milk of lactating rats. Because of the potential for adverse effects on the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug. Paediatric use Not to be used for children aged below 1 year of age. Pharmacokinetic information is limited in patients less than 6years. Use in the elderly Of the total number of hypertensive patients receiving OLMETEC in clinical studies, including two studies investigating safety and efficacy in the elderly, more than 40% were 65years of age and over, while more than 10% were 75years of age and older. No overall differences in effectiveness or safety were observed between elderly patients and younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. Genotoxicity Both olmesartan medoxomil and olmesartan tested negative in the in vitro Syrian hamster embryo cell transformation assay and showed no evidence of genetic toxicity in the Ames (bacterial mutagenicity) test. However, both were shown to induce chromosomal aberrations in cultured cells in vitro (Chinese hamster lung) and tested positive for thymidine kinase mutations in the in vitro mouse lymphoma assay. Olmesartan medoxomil tested negative in vivo for mutations in the intestine and kidney of a mutagenic susceptible mouse (MutaMouse) and for clastogenicity in mouse bone marrow (micronucleus test) at oral doses of up to 2,000mg/kg. Olmesartan not tested in this mouse model. On balance, the weight-of-evidence indicates that olmesartan medoxomil does not pose a genotoxic risk at clinically relevant doses. Carcinogenicity Olmesartan medoxomil was not carcinogenic when administered by dietary administration to rats for up to 2years. The highest dose tested (2,000mg/kg/day) corresponded to a relative systemic exposure to olmesartan that was about 30times that anticipated at the maximum recommended human dose (MRHD) of 40mg/day (based on AUC). Two carcinogenicity studies conducted in mice, a 6-month gavage study in the p53 knockout mouse and a 6-month dietary administration study in the Hras2 transgenic mouse, at doses of up to 1,000mg/kg/day (about 11times anticipated clinical exposure to olmesartan at the MRHD, based on AUC in Hras2), revealed no evidence of a carcinogenic effect of olmesartan medoxomil. Effects on ability to drive and use machines The effect of OLMETEC tablets on the ability to drive has not been specifically studied. With respect to driving vehicles or operating machines, it should be taken into account that occasionally dizziness or fatigue may occur in patients taking antihypertensive therapy. INTERACTIONS WITH OTHER MEDICINES Drugs that affect OLMETEC Potassium supplements and potassium sparing diuretics Based on experience with the use of other drugs that affect the renin-angiotensin system, concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other drugs that may increase serum potassium levels (e.g. heparin) may lead to increases in serum potassium. Such concomitant use is therefore not recommended. Other antihypertensive medications The blood pressure lowering effect of OLMETEC can be increased by concomitant use of other antihypertensive medications. Non-steroidal anti-inflammatory drugs (NSAIDs) NSAIDs (including acetylsalicylic acid at doses >3g/day and also COX-2 inhibitors) and angiotensinreceptor antagonists may act synergistically by decreasing glomerular filtration. The risk of the concomitant use of NSAIDs and angiotensin receptor antagonists is the occurrence of acute renal failure. Monitoring of renal function at the beginning of treatment should be recommended as well as regular hydration of the patient. Additionally, concomitant treatment can reduce the antihypertensive effect of angiotensin receptor antagonists, leading to their partial loss of efficacy. Other drugs After treatment with antacid (aluminium magnesium hydroxide), a modest reduction in bioavailability of olmesartan was observed. Coadministration of warfarin and digoxin had no effect on the pharmacokinetics of OLMETEC. Drugs that are affected by OLMETEC Lithium Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors and angiotensin receptor antagonists. Therefore use of OLMETEC and lithium in combination is not recommended (see PRECAUTIONS, Lithium). If use of the combination proves necessary, careful monitoring of serum lithium levels is recommended. Other drugs Drugs, which have been investigated in specific clinical studies in healthy volunteers, include warfarin, digoxin, an antacid (magnesium aluminium hydroxide), hydrochlorothiazide and pravastatin. No clinically relevant interactions were observed and in particular OLMETEC had no significant effect on the pharmacokinetics or pharmacodynamics of warfarin or the pharmacokinetics of digoxin. Olmesartan had no clinically relevant inhibitory effects on in vitro human cytochrome P450 enzymes 1A1/2, 2A6, 2C8/9, 2C19, 2D6, 2E1 and 3A4, and had no or minimal inducing effects on rat cytochrome P450 activities. Therefore in vivo interaction studies with known cytochrome P450 enzyme inhibitors and inducers were not conducted, and no clinically relevant interactions between olmesartan and drugs metabolised by the above cytochrome P450 enzymes are expected. ADVERSE EFFECTS OLMETEC has been evaluated for safety in more than 3,825 patients/subjects, including more than 3,275 patients treated for hypertension in controlled trials. This experience included about 900 patients treated for at least 6months and more than 525 for at least 1year. Treatment with OLMETEC was well tolerated, with an incidence of adverse events similar to placebo. Events generally were mild, transient and had no relationship to the dose of olmesartan medoxomil. The overall frequency of adverse events was not dose-related. Analysis of gender, age and race groups demonstrated no differences between olmesartan medoxomil and placebo-treated patients. The rate of withdrawals due to adverse events in all trials of hypertensive patients was 2.4% (i.e. 79/3,278) of patients treated with olmesartan medoxomil and 2.7% (i.e. 32/1,179) of control patients. In placebo-controlled trials, the only adverse event that occurred in more than 1% of patients treated with olmesartan medoxomil and at a higher incidence versus placebo was dizziness (2.5% versus 0.9%). Adverse events reported in placebo-controlled monotherapy studies with a greater than 1% incidence are shown in Table 6: Table 6. Clinical adverse effects (all causalities) occurring in e"1% of patients Body system Adverse eventNumber (%) patients with adverse eventPlacebo (n=555)10 mg (n=528)20 mg (n=566)40 mg (n=195)Body as a whole general disordersBack pain8 (1.4)5 (1.0)5 (0.9)3 (1.5)Chest pain3 (0.5)2 (0.4)4 (0.7)2 (1.0)Fatigue5 (0.9)7 (1.3)8 (1.4)0 (0.0)Headache48 (8.7)25 (4.7)32 (5.7)9 (4.6)Influenza-like symptoms18 (3.2)17 (3.2)17 (3.0)7 (3.6)Oedema peripheral4 (0.7)2 (0.4)3 (0.5)2 (1.0)Pain3 (0.5)3 (0.6)4 (0.7)3 (1.5)Central & peripheral nervous disordersDizziness 5 (0.9)8 (1.5)14 (2.5)6 (3.1)Gastrointestinal systemDiarrhoea3 (0.5)3 (0.6)6 (1.1)2 (1.0)Dyspepsia6 (1.0)1 (0.2)5 (0.8)1 (0.5)Gastroenteritis0 (0.0)3 (0.6)9 (1.6)0 (0.0)Nausea5 (0.9)1 (0.2)4 (0.7)4 (2.1)Tooth ache2 (0.4)1 (0.2)3 (0.5)3 (1.5)Liver and biliary system disordersBilirubinaemia2 (0.36)1 (0.2)5 (0.9)0 (0.0)Gamma-GT increased11 (2.0)15 (2.8)10 (1.8)4 (2.1)Increased SGOT6 (1.1)9 (1.7)1 (0.2)0 (0.0)Increased SGPT9 (1.6)9 (1.7)4 (0.7)2 (1.0)Metabolic and nutritional disorders Gout1 (0.2)2 (0.4)2 (0.4)2 (1.0)Creatine phosphokinase increased4 (0.7)2 (0.4)9 (1.6)1 (0.5)Hyperglycaemia14 (2.5)5 (1.0)7 (1.2)5 (2.6)Hypertriglyceridaemia6 (1.1)11 (2.1)12 (2.1)4 (2.1)Hyperuricaemia5 (0.9)5 (1.0)10 (1.8)0 (0.0)Musculoskeletal systemArthralgia4 (0.7)3 (0.6)6 (1.1)0 (0.0)Arthritis1 (0.2)3 (0.6)0 (0.0)2 (1.0)Skeletal pain3 (0.5)5 (1.0)6 (1.1)1 (0.5)Psychiatric disordersAnxiety2 (0.4)2 (0.4)2 (0.4)2 (1.0)Insomnia8 (1.4)1 (0.2)9 (1.6)1 (0.5)Reproductive disorders, maleImpotence0 (0.0)2 (0.4)2 (0.4)4 (2.1)Respiratory systemUpper respiratory tract infection26 (4.7)14 (2.7)10 (1.8)7 (3.6)Bronchitis10 (1.8)11 (2.1)12 (2.1)5 (2.6)Coughing4 (0.7)3 (0.6)6 (1.1)2 (1.0)Pharyngitis6 (1.1)9 (1.7)5 (0.9)1 (0.5)Rhinitis9 (1.6)9 (1.7)6 (1.1)2 (1.0)Sinusitis12 (2.2)6 (1.1)8 (1.4)2 (1.0)Secondary termsInflicted injury3 (0.5)7 (1.3)4 (0.7)1 (0.5)Urinary system disordersHaematuria10 (1.8)8 (1.5)15 (2.7)4 (2.1)Urinary tract infection4 (0.7)1 (0.2)6 (1.1)3 (1.5)Other adverse events of potential clinical relevance reported in the clinical trials are listed below. Adverse events reported across all clinical trials with olmesartan medoxomil (including trials with active as well as placebo control), irrespective of causality or incidence relative to placebo, included those events listed below. Frequencies are defined as: common ((1/100, <1/10); uncommon ((1/1,000, <1/100); rare ((1/10,000, <1/1,000), very rare (<1/10,000). Cardiovascular: Uncommon: Tachycardia; Rare: Hypotension Central nervous system: Uncommon: Vertigo Gastro-intestinal: Common: Abdominal pain Myo/endo/pericardial and valve disorders: Uncommon: Angina pectoris Musculoskeletal: Uncommon: Myalgia Skin and appendages: Uncommon: Rash Laboratory parameters In placebo-controlled monotherapy studies the incidence was somewhat higher on olmesartan medoxomil compared with placebo for hypertriglyceridaemia (2.0% versus 1.1%) and for raised creatine phosphokinase (1.3% versus 0.7%). Laboratory adverse events reported across all clinical trials with olmesartan medoxomil (including trials without a placebo control), irrespective of causality or incidence relative to placebo, included: Metabolic and nutritional: Uncommon: Hypercholesterolaemia, hyperlipaemia; Rare: Hyperkalaemia Post-marketing experience The following adverse reactions have been reported in post-marketing experience: Body as whole: Angioedema, asthenic conditions, such as asthenia, fatigue, lethargy, malaise, anaphylactic reactions Gastrointestinal: Abdominal pain, nausea, vomiting Liver and biliary system disorders: Hepatic enzymes increased Metabolic and nutritional disorders: Hyperkalaemia Musculoskeletal: Rhabdomyolysis, myalgia Nervous systems disorders: Headache Respiratory, thoracic and mediastinal disorders: Cough Skin and appendages: Alopecia, rash, pruritus, urticaria. Urogenital system: Acute renal failure, increased blood creatinine levels Use in elderly patients OLMETEC has been evaluated for safety in 1646 patients aged 65 years or older of whom, 454 were aged 75 years or older. Overall the incidence of adverse events in the elderly is comparable to that of the adult population. The number of withdrawals due to olmesartan medoxomil-related adverse effects was very low (6/1206; 0.5%) compared to the placebo (1/85; 1.2%) or losartan (0/184; 0.0%). Adverse events reported with olmesartan medoxomil monotherapy in the elderly with a greater than 1% incidence are shown in table 7: Table 7. Clinical adverse effects (all causalities) occurring in e"1% of elderly patients. Number (%) patients with adverse eventsBody system Adverse event20 mg OM (n = 742)40 mg OM (n = 464)Gastrointestinal disorders Diarrhoea7 (0.9%)5 (1.1%)Infections and infestations Bronchitis3 (0.4%)7 (1.5%) Bronchitis acute8 (1.1%)2 (0.4%) Influenza9 (1.2%)2 (0.4%) Nasopharyngitis16 (2.2%)2 (0.4%) Rhinitis9 (1.2%)2 (0.4%) Urinary tract infection10 (1.3%)7 (1.5%)Musculoskeletal and connective tissue disorders Arthralgia10 (1.3%)4 (0.9%) Back pain8 (1.1%)1 (0.2%)Nervous system disorders Dizziness9 (1.2%)8 (1.7%) Headache13 (1.8%)13 (2.8%)Respiratory, thoracic and mediastinal disorders Cough8 (1.1%)6 (1.3%)The most common adverse events considered to be treatment related in elderly patients were headache (1.5%) and dizziness (1.1%) on 40mg olmesartan medoxomil. Paediatric Use No clinically relevant differences were identified between the adverse experience profile for paediatric patients aged 1 to 18 years and that previously reported for adult patients. In placebo-controlled period, the only adverse event that occurred in more than 2% of patients treated with olmesartan medoxomil and at a higher incidence versus placebo was pseudohyperkalaemia (Cohort A: 1.1% versus 2.3%; Cohort C: 0% versus 7.1%). Clinical adverse effects (all causalities) occurring in e" 2% of patients aged 6-16 years (Cohorts A and B) and aged 1-5 years (Cohort C) versus placebo. Number (%) patients with adverse eventCohort ACohort BCohort CBody system Adverse eventOM (N = 93)Placebo (N = 89)OM (N = 53)Placebo (N = 54)OM (N = 29)Placebo (N = 28)Blood and lymphatic system disordersEosinophilia0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)1 (3.6)Gastrointestinal disordersDiarrhoea1 (1.1)0 (0.0)0 (0.0)0 (0.0)0 (0.0)1 (3.6)Vomiting3 (3.2)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)General disorders and administration site conditionsPyrexia3 (3.2) 0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)Infections and infestationsInfluenza0 (0.0)2 (2.3)2 (3.8)0 (0.0)1 (3.5)1 (3.6)Nasopharyngitis1 (1.1)0 (0.0)0 (0.0)1 (1.9)0 (0.0)2 (7.1)Pharyngitis2 (2.2)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)Upper respiratory tract infection1 (1.1)2 (2.3)0 (0.0)0 (0.0)1 (3.5)0 (0.0)Viral upper respiratory tract infection0 (0.0)1 (1.1)0 (0.0)0 (0.0)0 (0.0)1 (3.6)InvestigationsBlood urea increased0 (0.0)2 (2.3)0 (0.0)0 (0.0)0 (0.0)0 (0.0)Metabolism and nutrition disordersPseudohyperkalaemia1 (1.1)2 (2.3)0 (0.0)0 (0.0)0 (0.0)2 (7.1)Nervous system disordersDizziness1 (1.1)1 (1.1)0 (0.0)0 (0.0)0 (0.0)1 (3.6)Headache7 (7.5)3 (3.4)3 (5.7)1 (1.9)0 (0.0)0 (0.0)Respiratory, thoracic and mediastinal disordersCough4 (4.3)1 (1.1)1 (1.9)0 (0.0)1 (3.5)1 (3.6)Pharyngolaryngeal pain3 (3.2)0 (0.0)0 (0.0)1 (1.9)0 (0.0)0 (0.0)Rhinitis1 (1.1)0 (0.0)0 (0.0)1 (1.9)1 (3.5)0 (0.0)Rhinorrhoea2 (2.2)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)Skin and subcutaneous tissue disordersHyperhidrosis0 (0.0)0 (0.0)0 (0.0)0 (0.0)1 (3.5)0 (0.0)DOSAGE AND ADMINISTRATION Adults Dosage must be individualised. The optimal recommended starting dose of OLMETEC is 20mg once daily when used as monotherapy in patients who are not volume-contracted. If additional blood pressure reduction is required, the dose of OLMETEC may be increased to a maximum of 40mg daily. OLMETEC may be administered with or without food. In order to assist compliance, it is recommended that OLMETEC tablets be taken at about the same time each day. Twice-daily dosing offers no advantage over the same total dose given once daily. The antihypertensive effect of olmesartan medoxomil is substantially present within 2weeks of initiating therapy and is maximal by about 8weeks after initiating therapy. This should be borne in mind when considering changing the dose regimen for any patient. Hydrochlorothiazde therapy should be considered in those patients requiring additional blood pressure control beyond 40mg daily. OLMETEC may be administered with other antihypertensive agents. Special populations Elderly No dosage adjustment is necessary. If up-titration to the maximum dose of 40 mg daily is required, blood pressure should be closely monitored. Renal insufficiency No adjustment of dosage is required for patients with mild (creatinine clearance of 5080mL/min, eGFR 60-89mL/min/1.73m2) to moderate (creatinine clearance of 30<50mL/min, eGFR 30-59mL/min/1.73m2) renal impairment. The use of OLMETEC in patients with severe renal impairment (creatinine clearance <30mL/min, eGFR <30mL/min/1.73m2) is not recommended, since there is only limited experience in this patient group (see PRECAUTIONS, Renal impairment and kidney transplantation). There are no data on the use of olmesartan in children with eGFR less than 25mL/min/1.73m2. Intravascular volume depletion For patients with possible depletion of intravascular volume, particularly those with impaired renal function, OLMETEC should be administered under close medical supervision. In these patients a lower starting dose of 10mg once daily is recommended (see PRECAUTIONS, Intravascular volume depletion) (see PRESENTATIONS AND STORAGE CONDITIONS for marketed strengths). If a patient becomes volume depleted whilst taking OLMETEC, blood pressure and renal function should be closely monitored until the situation resolves. Hepatic insufficiency No adjustment of dosage is required for patients with mild (Child-Pugh score 5-6) to moderate (Child-Pugh score 7-9) hepatic impairment. Close monitoring of blood pressure and renal function is advised in hepatically-impaired patients who are already receiving diuretics and/or other antihypertensive agents. There is no experience of olmesartan medoxomil in patients with severe (Child-Pugh score 10-15) hepatic impairment (see PRECAUTIONS, hepatic impairment). If up-titration of OLMETEC to the maximum dose of 40mg daily is required, blood pressure should be closely monitored. Paediatric Use Dosing must be individualised. The recommended starting dose of OLMETEC is based on age and/or weight (see Dosing recommendation table). If after 2 weeks of therapy further reduction in blood pressure is required, the dose of OLMETEC may be increased to a maximum of either 20 mg or 40 mg (see Dosing recommendation table). There are limited data available for the pharmacokinetics of olmesartan in children aged less than 6 years (see PHARMACOLOGY, Pharmacokinetics in special populations, Paediatric) and there are no pharmacokinetic data available in children with renal impairment (see DOSAGE AND ADMINISTRATION, Renal insufficiency). Dosing recommendations Age GroupWeightStarting Dose Once dailyDose Range Once dailyMaximum dose Once daily1-5 yearse" 5 kg0.3 mg/kg Max: 10 mg0.3  0.6 mg/kg Max: 20 mg20 mg6-18 yearse" 20 kg and < 35 kg10 mg10  20 mg20 mge" 35 kg20 mg20  40 mg40 mgFor children who cannot swallow tablets, the equivalent dose may be given as an extemporaneous suspension [see DOSAGE AND ADMINISTRATION, Special Populations, Preparation of Suspension]. If 10mg tablets are not available, the extemporaneous suspension may be used. Preparation of Suspension by compounding pharmacist (for 200 mL of a 2 mg/mL suspension) The suspension is prepared in an amber polyethylene terephthalate (PET) bottle with a child resistant closure. The amber PET bottle should be of a suitable size e.g. 240mL*. * The stability of the suspensions in larger bottles has not been established. Add 50 mL of purified water to an amber PET bottle containing twenty OLMETEC 20 mg tablets and allow it to stand for a minimum of 5 minutes to allow complete disintegration. Shake the container for at least 1minute and allow the suspension to stand for at least 1minute. Repeat 1-minute shaking and 1-minute standing steps for four additional times. Add 100 mL of Ora-Sweet* and 50mL of Ora-Plus* to the suspension and shake well for at least 1 minute. * Ora-Sweet and Ora-Plus are registered trademarks of Paddock Laboratories, Inc. The suspension cannot be prepared using water only and the tablets should not be ground before use. Only 20mg OLMETEC tablets may be used in preparing the suspension. For handling and storage instruction, see PRESENTATION AND STORAGE CONDITIONS. OVERDOSAGE Only limited information is available regarding overdosage in humans. The most likely effect of overdosage is hypotension and tachycardia; bradycardia could be encountered if parasympathetic $%&<=R           5 A   2 4 ΰΫΫΤΒΒ΂h ,fHmH q sH h ,fHq h ,^J h ,H*^J h ,6jh: bUmHnHsH uh ,5OJQJ h ,H*h ,h ,CJaJmH sH h ,5CJaJmH sH  jh ,aJmH sH h ,mH sH 3=R 5 A fQQP<<H` "##5#Q#$$<$Ifa$gdj $<$Ifgdjgdgd  !4!m!}!!!"x"y"~""""""#####4#5#P#Q#R#S#V#^#_#i#j#s#t#u#x#o$hjhjCJOJQJaJmHsH'hjhjCJH*OJQJaJmH sH h-Jhj$h-JhjCJOJQJaJmH sH hjCJOJQJaJmH sH hjhH* hjH* h ,]hGDChjhhyxph  jh ,aJh ,h ,fHq (Q#R#_#j#t#pcSS$$<$Ifa$gdj $<$Ifgdjkd$$Ifl4F #   0#    44 lalf4ytjt#u####pcSS$$<$Ifa$gdj $<$Ifgdjkd$$Ifl4F #   0#    44 lalf4ytjx#{########$$$0$2$H$J$L$N$T$^$`$r$t$$$$$$$$$$$$$$$$$%% % %ȵȵȵȵȁȵȵȵȁȵȵȵȵȵȵk*hjhjCJH*OJQJ\aJmH sH 'hjhjCJH*OJQJaJmH sH %hjCJH*OJQJ^JaJmHsHhhjB*CJph$hhjCJOJQJaJmH sH hjCJOJQJaJmH sH $hjhjCJOJQJaJmHsH'hjhjCJH*OJQJaJmHsH*##$2$J$pcSS$$<$Ifa$gdj $<$Ifgdjkd4$$Ifl4F #   0#    44 lalf4ytjJ$L$`$t$$pcSS$$<$Ifa$gdj $<$Ifgdjkd$$Ifl4F #   0#    44 lalf4ytj$$$$$pcSS$$<$Ifa$gdj $<$Ifgdjkdh$$Ifl4F #   0#    44 lalf4ytj$$$$%pcSS$$<$Ifa$gdj $<$Ifgdjkd$$Ifl4F #   0#    44 lalf4ytj% %%pe <$Ifgd:kd$$Ifl4F #   0#    44 lalf4ytj %%%%\&_&&&(())**#,$,*-+-a-b----..L.M.......//[/\///////þòòþêææáÎsss'h-Jh ,CJH*OJQJaJmH sH h-Jh ,$h-Jh ,CJOJQJaJmH sH h ,H*hyxph ,mH sH h ,fHq h ,H*h ,hh5B*CJ\ph'hjhCJOJQJ\aJmH sH 'hjhjCJOJQJ\aJmH sH *%%%&&'((**$-----~~~<$Ifd[$gdikd6$$Ifl4##0#44 lalf4yt----$ _<$Ifa$<$If---...<4444<$Ifkd$$Ifl4ֈO bup#O0p#44 lalf4....!kd$$Ifl4ֈO bup#O0p#44 lalf4$ _<$Ifa$<$If.+.4.6.B.D.L. $<$Ifa$<$IfL.M.].g.s..<4444<$Ifkd$$Ifl4ֈO bup#O0p#44 lalf4.....'kd$$Ifl4ֈO bup#O0p#44 lalf4 $<$Ifa$<$If...... $<$Ifa$<$If...../<4444<$Ifkd|$$Ifl4ֈO bup#O0p#44 lalf4////,/'kdi $$Ifl4ֈO bup#O0p#44 lalf4 $<$Ifa$<$If,/8/D/P/R/[/ $<$Ifa$<$If[/\/n/x///<4444<$IfkdV $$Ifl4ֈO bup#O0p#44 lalf4/////'kdC $$Ifl4ֈO bup#O0p#44 lalf4 $<$Ifa$<$If///3 3)3*3J3K3m33344Y4Z4445 5`5a5b5555273788::;;;;:<;<J<K<<<<<<<ͷ߫߫ߡߡyuuh65qh;>GaJnHtHhyxpaJnHtHh!aJnHtHh65qaJnHtHh ,aJnHtHh ,fHq h-Jh ,5CJ\h-Jh ,CJH*h-Jh ,CJ h ,H*hyxph , h-Jh ,*h-Jh ,5CJOJQJ\aJmH sH -//0#3m3x333 9r n<$Ifd[$gdckd0 $$Ifl4p#p#0p#44 lalf433333334ugggggg 9r n<$Ifkd $$Ifl4FOp#`M`n!0#    44 laf444 44#464<.... 9r n<$Ifkda $$Ifl4ֈOp# M n0#44 laf464G4Y4Z4a4g41kd1$$IflֈOp#Mn0#44 la 9r n<$Ifg4z444441kd$$IflֈOp#Mn0#44 la 9r n<$If4444445 9r n<$If5 555*5<5?1111 9r n<$Ifkd$$IflֈOp#Mn0#44 la<5N5`5a551kdq$$IflֈOp#Mn0#44 la 9r n<$If55 788::<<<="=}mm$$<$Ifa$gd: $<$Ifgd:gd65qd[$gd'%ckd1$$Ifl4p##0#44 laf4 <<<<<==!="=#=.=/=9=:=>=@=D=E=F=G=S=_=`=a=f=h=m=n=o=p=|=====һҫ˜wdWwhh65qB*CJph$hh65qCJOJQJaJmH sH 'h!h65qCJH*OJQJaJmH sH !h!CJH*OJQJaJmH sH h+h65qCJOJQJaJh+CJOJQJaJmH sH h!CJOJQJaJmH sH h-Jh65q$h-Jh65qCJOJQJaJmH sH h65qCJOJQJaJmH sH h!h65qh!""=#=/=:=F=pcSS$$<$Ifa$gd: $<$Ifgd:kd$$Ifl4F #   0#    44 lalf4yt:F=G=S=a=o=pcSS$$<$Ifa$gd: $<$Ifgd:kdM$$Ifl4F #   0#    44 lalf4yt:o=p=|===pcSS$$<$Ifa$gd: $<$Ifgd:kd$$Ifl4F #   0#    44 lalf4yt:======================== > >>>>&>'>.>/>0>=>>>F>G>H>L>M>V>W>a>xxoxxoxxoxxoxxohh!CJ$hh!CJOJQJaJmH sH 'h!h65qCJH*OJQJaJmH sH !h!CJH*OJQJaJmH sH h65qCJOJQJaJmH sH hh65qB*CJph$hh65qCJOJQJaJmH sH h+CJOJQJaJmH sH h!CJOJQJaJmH sH +=====pcSS$$<$Ifa$gd: $<$Ifgd:kd$$Ifl4F #   0#    44 lalf4yt:=====pcSS$$<$Ifa$gd: $<$Ifgd:kd$$Ifl4F #   0#    44 lalf4yt:=====p_OO$$<$Ifa$gd:$<$If^gd!kd$$Ifl4F #   0#    44 lalf4yt:=====p_OO$$<$Ifa$gd:$<$If^gd!kdO$$Ifl4F #   0#    44 lalf4yt:==> >>p_OO$$<$Ifa$gd:$<$If^gd!kd$$Ifl4F #   0#    44 lalf4yt:>>>'>/>p_OO$$<$Ifa$gd:$<$If^gd!kd$$Ifl4F #   0#    44 lalf4yt:/>0>6>>>G>p_OO$$<$Ifa$gd:$<$If^gd!kd$$Ifl4F #   0#    44 lalf4yt:G>H>M>W>b>pcSS$$<$Ifa$gd: $<$Ifgd:kd$$Ifl4F #   0#    44 lalf4yt:a>b>c>>>>>>>>>>>>>>>>>>(@@BZD^DcDhDDEннннk[WSWIWIWIWh ,aJnHtHhGDCh ,hh65q5B*CJ\ph'h!h!CJOJQJ\aJmH sH !h!\0CJOJQJ\aJmH sH !h!CJOJQJ\aJmH sH $h!CJH*OJQJ\aJmH sH hh!CJ$hh!CJOJQJaJmH sH h!CJOJQJaJmH sH hh65qB*CJph$hh65qCJOJQJaJmH sH b>c>x>>>pcSS$$<$Ifa$gd: $<$Ifgd:kdQ$$Ifl4F #   0#    44 lalf4yt:>>>>>pcSS$$<$Ifa$gd: $<$Ifgd:kd$$Ifl4F #   0#    44 lalf4yt:>>>pe <$Ifgd:kd$$Ifl4F #   0#    44 lalf4yt:>>@B+EmG#H6Hzxsc$$<$Ifa$gd:gd6J7$8$H$ 7$8$H$gd* d7$8$H$[$gd'%ikd$$Ifl4##0#44 lalf4yt:E$E%E)E*E+EFFFF4G8GAGLGWGlGmGsGtGvGGGGGHH"H#H5H6H7H8H=H>HCHDHEHFHQHĽ||ub$hjhkCJOJQJaJmHsH h-Jh6Jh6JCJOJQJaJmH sH $h-Jh6JCJOJQJaJmH sH h-Jhk hkhkhkCJOJQJaJmH sH h!h6Jh+h6Jh!\0hyxph= Vh*h ,aJnHtHh ,h ,5\aJmH sH h ,aJmH sH &6H7H8H>HDHww$$<$Ifa$gd: $<$Ifgd:kkd$$Ifl4##044 lalf4ytkDHEHFH]H}HHHpcSSSS$$<$Ifa$gd: $<$Ifgd:kd?$$Ifl4F #   0    44 lalf4ytkQHRH\H]H|H}HHHHHHHHHHHHHHHHHH I I I I޸޸nn[[Rhh= VCJ$hh= VCJOJQJaJmH sH $h6Jh= VCJOJQJaJmH sH h= VCJOJQJaJmH sH hkh= VCJOJQJaJhkhkCJOJQJaJhhkCJ$hhkCJOJQJaJmH sH $h6JhkCJOJQJaJmH sH hkCJOJQJaJmH sH !h= VCJH*OJQJaJmH sH HHH/" $<$Ifgdkkd$$Ifl4r # @044 lalf4p2ytkHHHHHH Iqqqq$$<$Ifa$gd:$<$If^`gdkikd$$Ifl4##044 lalf4ytk I I2I/" $<$Ifgdkkdl$$Ifl4r # @044 lalf4p2ytk I+I1I2I3IAIBIOIPI[I\IgIhIsItIuIIIIIIIIIIIIIIIIIIIIIIIIIIJJJJ'Jss!h= VCJH*OJQJaJmH sH $hjh= VCJOJQJaJmHsH h-Jh= V$h-Jh= VCJOJQJaJmH sH $h6Jh= VCJOJQJaJmH sH hh= VCJ$hh= VCJOJQJaJmH sH h= VCJOJQJaJmH sH h!\0CJOJQJaJmH sH -2I3IBIPI\IhItIuuuu$$<$Ifa$gd:$<$If^gdkikdu$$Ifl4##044 lalf4ytktIuII/$<$If^gdkkd$$Ifl4r # @044 lalf4p2ytkIIIII$$<$Ifa$gd:III/$$<$Ifa$gd:kd $$Ifl4r # @044 lalf4p2ytkIIIIIww$$<$Ifa$gd: $<$Ifgd:kkd!$$Ifl4##044 lalf4ytkIIIIJ(JGJpcSSSS$$<$Ifa$gd: $<$Ifgd:kd!$$Ifl4F #   0    44 lalf4ytk'J(JFJGJHJTJ[J\J]JfJuJvJJJJJJJJJJJJJJJJJJJJJJJ KKKK K/K=K>KIKJKUKVKaKbKcKKKĴݴݴ݁Դh!\0CJOJQJaJmH sH h+XCJOJQJaJmH sH $h6Jh= VCJOJQJaJmH sH h= VCJOJQJaJmHsHh!\0CJOJQJaJmHsHhh= VCJh= VCJOJQJaJmH sH $hh= VCJOJQJaJmH sH 2GJHJ\J/" $<$Ifgdkkd9"$$Ifl4r # @044 lalf4p2ytk\J]JvJJJJJuuuu$$<$Ifa$gd:$<$If^gd6JikdB#$$Ifl4##044 lalf4ytkJJJ/$<$If^gd6Jkd#$$Ifl4r # @044 lalf4p2ytkJJJJJ$$<$Ifa$gd:JJK/" $<$Ifgdkkd$$$Ifl4r # @044 lalf4p2ytkK K0K>KJKVKbKuuuu$$<$Ifa$gd:$<$If^gdkikd%$$Ifl4##044 lalf4ytkbKcKsK/$<$If^gdkkdh&$$Ifl4r # @044 lalf4p2ytksKKKKK$$<$Ifa$gd:KKKKKKKKKKKKKKKKLLLMMMMMMMOOOOPQS7S9TeTjUtUUU_V𯟛ttttplg h H*h hyxph ,fHmH q sH h ,mH sH hzrh ,h!\0hGDCh ,hh= V5B*CJ\ph'h= Vh= VCJOJQJ\aJmH sH !h= VCJH*OJQJaJmH sH hh= VCJ$hh= VCJOJQJaJmH sH h= VCJOJQJaJmH sH (KKK/$ <$Ifgd:kdq'$$Ifl4r # @044 lalf4p2ytkKKMMMM NnNN OOOOPQ$a$d[$gd'%ikdz($$Ifl4##044 lalf4ytkQS7S9TeTVVWWXXhYYRZhZ@[S[V\\E_K_`'`Aa_abiefShi_ViVwVxVzVVVVVVVWWWXXhYYRZhZ@[R[S[V\\E_K_``'`````@aAa_aj jllmmnnKo[o\opppp q qqqLsYsssǽ h ,6hh ,5\hhsk{ jh ,aJ h ,H* h ,6 h ,h h ,>*h ,mH sH h ,fHmH q sH h h , h} /H*h} /h , h H*h hyxp;iskKo\opp qqLsYsvvYyyzzz{u||}@}s&2G$H$svt~tttuuuuuvvvww)w*wawwwwxxxxXyYyyyzzz{u||}@}&2~( h-Jh ,)h-Jh ,B*CJOJQJ^JaJphh'%hyxp h ,6h ,fHmHq sHh ,fHq h ,fHmH q sH h ,mH sH h , h ,6h h ,h92sɉ(@\rxkd )$$Ifl440f\$`a0W$44 laqf4 $$Ifa$$If ΋6E?$Ifkd)$$Ifl44rfa\$ a}~}~0W$44 laqf4 $$Ifa$67ab RSxy͍΍<=mnŽMN}~ҏӏ=>noِؐGHvw h-Jh ,CJOJQJ^JaJ&h-Jh ,6CJOJQJ]^JaJ)h-Jh ,B*CJOJQJ^JaJph h-Jh ,/h-Jh ,6B*CJOJQJ]^JaJphA67AIQYa $$Ifa$ $If^ckd|*$$Ifl4\$W$0W$44 laqf4abmu}RH???? $$Ifa$ $If^kd*$$Iflrfa\$a}~}~0W$44 laqRH???? $$Ifa$ $If^kd+$$Iflrfa\$a}~}~0W$44 laqɌҌیRH???? $$Ifa$ $If^kd,$$Iflrfa\$a}~}~0W$44 laqRH???? $$Ifa$ $If^kdV-$$Iflrfa\$a}~}~0W$44 laq 2:BJRRH???? $$Ifa$ $If^kd!.$$Iflrfa\$a}~}~0W$44 laqRSX`hpxRH???? $$Ifa$ $If^kd.$$Iflrfa\$a}~}~0W$44 laqxyRL$Ifkd/$$Iflrfa\$a}~}~0W$44 laqō͍ $$Ifa$ $If^ckd0$$Ifl4\$W$0W$44 laqf4͍΍RL$Ifkd0$$Iflrfa\$a}~}~0W$44 laq  $$Ifa$ $If^ckd1$$Ifl4\$W$0W$44 laqf4$,4<RH???? $$Ifa$ $If^kd?2$$Iflrfa\$a}~}~0W$44 laq<=MU]emRH???? $$Ifa$ $If^kd 3$$Iflrfa\$a}~}~0W$44 laqmnu}RH???? $$Ifa$ $If^kd3$$Iflrfa\$a}~}~0W$44 laqRH???? $$Ifa$ $If^kd4$$Iflrfa\$a}~}~0W$44 laqŽRL$Ifkdk5$$Iflrfa\$a}~}~0W$44 laq $$Ifa$ $If^ckd66$$Ifl4\$W$0W$44 laqf4*3<EMRH???? $$Ifa$ $If^kd6$$Iflrfa\$a}~}~0W$44 laqMN]emu}RH???? $$Ifa$ $If^kdz7$$Iflrfa\$a}~}~0W$44 laq}~RH???? $$Ifa$ $If^kdE8$$Iflrfa\$a}~}~0W$44 laqҏRL$Ifkd9$$Iflrfa\$a}~}~0W$44 laqҏӏۏ $$Ifa$  $Ifckd9$$Ifl4\$W$0W$44 laqf4%-5=RH???? $$Ifa$ $If^kdT:$$Iflrfa\$a}~}~0W$44 laq=>MV^fnRH???? $$Ifa$ $If^kd;$$Iflrfa\$a}~}~0W$44 laqnoRH???? $$Ifa$ $If^kd;$$Iflrfa\$a}~}~0W$44 laqǐАؐRH???? $$Ifa$ $If^kd<$$Iflrfa\$a}~}~0W$44 laqِؐRL$Ifkd=$$Iflrfa\$a}~}~0W$44 laq  $$Ifa$ $If^ckdK>$$Ifl4\$W$0W$44 laqf4'/7?GRH???? $$Ifa$ $If^kd>$$Iflrfa\$a}~}~0W$44 laqGHV^fnvRH???? $$Ifa$ $If^kd?$$Iflrfa\$a}~}~0W$44 laqvwRL$IfkdZ@$$Iflrfa\$a}~}~0W$44 laq $$Ifa$ $If^ckd%A$$Ifl4\$W$0W$44 laqf4ȑБؑRH???? $$Ifa$ $If^kdA$$Iflrfa\$a}~}~0W$44 laq)*=>_`hiqrz{ܒݒ 34_`pqȓ#$İİİİİvv jh ,aJh ,)h-Jh ,B*CJOJQJ^JaJph/h-Jh ,6B*CJOJQJ]^JaJph'h ,B*CJOJPJQJ^JaJphh ,B*CJOJPJQJph&h-Jh ,6CJOJQJ]^JaJ h-Jh ,CJOJQJ^JaJ h-Jh ,.RL$IfkdiB$$Iflrfa\$a}~}~0W$44 laq !) $$Ifa$ $If^ckd4C$$Ifl4\$W$0W$44 laqf4)*=RL$IfkdC$$Iflrfa\$a}~}~0W$44 laq=>`ir{ $$Ifa$ $If^ckdxD$$Ifl4\$W$0W$44 laqf4RH???? $$Ifa$ $If^kdD$$Iflrfa\$a}~}~0W$44 laqĒ̒ԒܒRH???? $$Ifa$ $If^kdE$$Iflrfa\$a}~}~0W$44 laqܒݒ RH???? $$Ifa$ $If^kdF$$Iflrfa\$a}~}~0W$44 laq #+3RH???? $$Ifa$ $If^kdRG$$Iflrfa\$a}~}~0W$44 laq34>GOW_RH???? $$Ifa$ $If^kdH$$Iflrfa\$a}~}~0W$44 laq_`pRL$IfkdH$$Iflrfa\$a}~}~0W$44 laqpq $$Ifa$ $If^ckdI$$Ifl4\$W$0W$44 laqf4RL$Ifkd,J$$Iflrfa\$a}~}~0W$44 laqȓѓٓ $$Ifa$ $If^ckdJ$$Ifl4\$W$0W$44 laqf4 #RH???? $$Ifa$ $If^kdpK$$Iflrfa\$a}~}~0W$44 laq#$3^ΖRPIIIIII j:kd;L$$Iflrfa\$a}~}~0W$44 laq͕̕ 2J]r͖ޖ.ۘ:T+MqϚ =BW}Ǜߛý~ h-Jh ,&h-Jh ,5CJOJQJ\^JaJhyxp h ,0J6]^JaJmH sH h ,0J]^JaJmH sH h ,0J#h ,6]^JaJhmH sH h ,hh ,mH sH h ,fHq h ,6] jh ,aJh ,/.ۘ:TM C}Ǜߛi*$$If *$$$Ifa$  ff^f`Blxpp*$$If*$$ $Ifa$ *$$$Ifa$kkdM$$If440U" 44 af4pln ,-QRopޠߠ/0;MNfghԡա֡ʥԥ֥龭镍zh-Jh ,CJ^JnH tH h'%h ,mH sH h ,&h-Jh ,6OJQJ]^JmHsH h-Jh ,OJQJ^JmHsHh-Jh ,OJQJ^Jh-Jh ,OJQJ]^Jh-Jh ,6OJQJ]^J h-Jh ,h-Jh ,5OJQJ\^J/lnujLkdN$$If4U"i"  44 af4p +$$$Ifa$kdM$$If44FU"j j      44 af4pΟ \Q +$$$Ifa$kdO$$If4FU"j j      44 af4p +$$$Ifa$+$$ $Ifa$ #, +$$$Ifa$+$$ $Ifa$LkdO$$If4U"i"  44 af4p ,-?HQwg\\ +$$$Ifa$+$$ $Ifa$kdMP$$If4FU"j j      44 af4pQR]fowg\\ +$$$Ifa$+$$ $Ifa$kd"Q$$If4FU"j j      44 af4popwg\\ +$$$Ifa$+$$ $Ifa$kdQ$$If4FU"j j      44 af4pwg\\ +$$$Ifa$+$$ $Ifa$kdR$$If4FU"j j      44 af4pˠՠޠwg\\ +$$$Ifa$+$$ $Ifa$kdwS$$If4FU"j j      44 af4pޠߠwl LkdU$$If4U"i"  44 af4p +$$$Ifa$kd>T$$If4FU"j j      44 af4p&/0;DM]kdU$$If4FU"j j      44 af4p +$$$Ifa$+$$ $Ifa$MNghwlNkdW$$If4U"i"  44 af4p +$$$Ifa$kdQV$$If4FU"j j      44 af4phs|]kdW$$If4FU"j j      44 af4p +$$$Ifa$+$$ $Ifa$ա֡wl Lkd!Y$$If4U"i"  44 af4p +$$$Ifa$kdZX$$If4FU"j j      44 af4p֡ݡS̥]YWUUUkdY$$If4FU"j j      44 af4p +$$$Ifa$+$$ $Ifa$ ̥Х֥&/RkdmZ$$Ifl40g @#v O#44 la] $$Ifa$֥/0<LMʦ˦ $%_`ϧЧ &'abߨ23JKde٪ڪ ABëī()ghźh ,fHmH q sH h ,\hmH sH h ,mH sH "h-Jh ,6CJ]^JnH tH h-Jh ,h-Jh ,CJ^JnH tH h-Jh ,^JaJC/0MYjv~ssssss $$Ifa$$IfxkdZ$$Ifl4\g @#v )XXO#44 la]ʦME$Ifkd[$$Ifl4֞g (@#v h__O#44 la]ʦ˦ئ $$Ifa$ $If^?kd\$$Ifl4+@#O#O#44 la] $ME$Ifkd+]$$Ifl4֞g (@#v h__O#44 la]$%/7?GOW_ $$Ifa$ $If^?kd9^$$Ifl4%@#O#O#44 la]_`iqyMA6666 $$Ifa$ $If^kd^$$Ifl4֞g (@#v h__O#44 la]ϧB:$Ifkd_$$Ifl4֞g (@#v h__O#44 la] $$Ifa$ϧЧا $$Ifa$ $If^?kd`$$Ifl4@#O#O#44 la] &ME$Ifkd1a$$Ifl4֞g (@#v h__O#44 la]&'19AIQYa $$Ifa$ $If^?kd?b$$Ifl4@#O#O#44 la]abrzMA6666 $$Ifa$ $If^kdb$$Ifl4֞g (@#v h__O#44 la]B6 $If^kdc$$Ifl4֞g (@#v h__O#44 la] $$Ifa$ǨϨרߨB6 $If^kdd$$Ifl4֞g (@#v h__O#44 la] $$Ifa$ "*23Bkde$$Ifl4֞g (@#v h__O#44 la] $$Ifa$3[cks{ $$Ifa$ $If^ME$Ifkdf$$Ifl4֞g (@#v h__O#44 la]ɩѩ٩ $$Ifa$ $If^?kdg$$Ifl4@#O#O#44 la]ME$Ifkdah$$Ifl4֞g (@#v h__O#44 la]"*2:BJ $$Ifa$ $If^?kdoi$$Ifl4@#O#O#44 la]JKdME$Ifkdi$$Ifl4֞g (@#v h__O#44 la]deow $$Ifa$ $If^?kdj$$Ifl4O@#O#O#44 la]ɪMA6666 $$Ifa$ $If^kdYk$$Ifl4֞g (@#v h__O#44 la]ɪѪ٪ڪ B:$Ifkdgl$$Ifl4֞g (@#v h__O#44 la] $$Ifa$ !)19A $$Ifa$ $If^?kdum$$Ifl40@#O#O#44 la]ABYaiqyMA6666 $$Ifa$ $If^kdm$$Ifl4֞g (@#v h__O#44 la]yB6 $If^kdn$$Ifl4 ֞g (@#v h__O#44 la] $$Ifa$ëīЫB6 $If^kdo$$Ifl4֞g (@#v h__O#44 la] $$Ifa$ЫثBkd q$$Ifl4֞g (@#v h__O#44 la] $$Ifa$()7?GOW_g $$Ifa$ $If^?kdr$$Ifl4@#O#O#44 la]$If ghfMECAAAAd[$gd'%kdr$$Ifl4֞g (@#v h__O#44 la]fyz$%ױcjm{|jklmLM 䯣~hsk{^JaJnH tH h\6^JaJnH tH h\^JaJnH tH h} /^JaJnH tH h ,^JaJnH tH h ,]mH sH h ,fHq h} /h} / h} /H*h} /hyxph ,fHmH q sH h ,h ,mH sH .fz%mɺߺ $x$Ifa$x$If7$8$H$ d7$8$H$\$gd'%!z|*,PQVW 5;CQ···ܪ܌܌}piWW"hv h ,5>*^JaJnH tH h<h ,h ,\^JaJnH tH h ,5\^JaJnH tH h!=h ,^JaJnH tH h ,6]^JaJnH tH h ,]^JaJnH tH h-Jh ,^JaJh-Jh ,aJ h-Jh ,h-Jh ,5aJh ,^JaJnH tH h} /^JaJnH tH h65q^JaJnH tH "8nzNF;;;; $x$Ifa$x$Ifkds$$Iflrw+H# t0644 laz|ƼܼNF;;;; $x$Ifa$x$IfkdXt$$Iflrw+H# t0644 la*LD9999 $x$Ifa$x$Ifkdu$$Ifl4rw+H#` t0644 la*,QL==;;d7$8$H$[$gd'%kdu$$Ifl4rw+H#  t0644 laQBW|LTMxMMNNjNwNNNN*OPPP"QBQbQQQQQQQQQ(Rʻzsnfa h ,H*h#)dh ,\ h#)d\ h#)d5\h ,5\mH sH h ,0J. h ,5\ jh ,aJ h ,0J'Uh ,h ,mH sH hsk{^JaJnH tH h:_h ,^JaJnH tH h'%CJ^JnH tH h ,CJ^JnH tH "hv h ,5>*^JaJnH tH h ,^JaJnH tH %LLTMxMNjNNN*OOQPPP"QBQbQQQ R*R,R-R$a$d[$gd'%d7$8$H$[$gd'%7$8$H$(vagal) stimulation occurs. In the event of overdosage, the patient should be carefully monitored and treatment should be symptomatic and supportive. No information is available regarding the dialysability of olmesartan. For further advice on the management of an overdose contact the Poisons Information Centre (on 131126 in Australia). PRESENTATION AND STORAGE CONDITIONS 10mg tablet: White, circular film-coated tablet with C13 embossed on one side. Blister pack of 30. Not currently available in Australia 20mg tablet: White, circular film-coated tablet with C14 embossed on one side. Blister pack of 30. 40mg tablet: White, oval film-coated tablet with C15 embossed on one side. Blister pack of 30. Store below 25(C. Extemporaneous suspension: Store between 2-8C (Refrigerate; Do not freeze) The suspension should be refrigerated at 2-8C (DO NOT FREEZE) and can be stored for up to 4 weeks. Shake the suspension well before each use and return promptly to the refrigerator. An appropriate measuring device (syringe or measuring cup) should be used for the volume to be administered. Any unused suspension MUST be discarded after 28 days from the date of preparation. NAME AND ADDRESS OF THE SPONSOR Merck Sharp & Dohme (Australia) Pty Limited 54 68 Ferndell Street South Granville NSW 2142 POISON SCHEDULE OF THE MEDICINE Prescription only medicine (S4) DATE OF FIRST INCLUSION IN THE AUSTRALIAN REGISTER OF THERAPEUTIC GOODS (ON ARTG) 6 Sept 2005 DATE OF MOST RECENT AMENDMENT: 13 Sept 2012 Registered Trademark of Daiichi Sankyo Company Ltd Version 7     Attachment 1: Product information for AusPAR Olmetec Merck Sharp & Dohme (Australia) Pty Ltd PM-2011-01941-3-3 Final 26 February 2013. This Product Information was approved at the time this AusPAR was published. Olmetec PI v7 A120913 CCDS ref v6 101130 LRN S-000000-OLM-TB-PIPB.1 Page  PAGE 20 EMBED Word.Picture.8 (R)R*R+R-R.R0R1R3R4R6R S SSSSSSS STSUS[S\S^S_S`SaSbScSwSxSySzS{S|S}S¼±ح욌vc_hZ#$jvh4h: bCJUmHnHu*j¸S h4h: bCJUVmHnHuh4h: bCJmHnHu$jh4h: bCJUmHnHuh: bhNO0J"mHnHu h: b0J"jh: b0J"U hyxpaJ h#)daJ h: baJh-Rdh-Rd5CJOJQJh jh Uh ,h#)d$-R/R0R2R3R5R6R S S`SaSbS{S|S}S  9r }#6/$d%d&d'd-DM NOPQgd-RdF00P&P 1h:p4. A!"#$%tS Dp`!%]u-=[X\xO\~ф֤v.RkJ!$.xZ^tJHV) ^Np- C3,MK)Ub68$Nd dPkd4tH9s9{ҹzy}9p9~sB>->i|gҟX>}/Qq>O~7 秾_O/?ԑ?|_'wNO~Bgk~?}}k7*~7nsOwSv?~cj?#*"/?kBпo!ջƿ"o<~?ok|g[|Gv?>7>vq'w/gVh*7.~*A4~z7T_oaX}3SAmnY_O.O0L__4\Q?_}3?~ϣo??*~߽g5}ߪcWnoUg?'_O?~Wo7dP9ޕo߽7J_'׫_~ ?YUUɗ*mTaU:?'q~~~~G~~~~~~~~G~~~~~~G~~~~~G~~~~G~G~~~~G~~~~~G~~~~~~~~G~~~~~~G~~~~~G~~~~G~G~~~~G~~~~~G~~~~~~~~G~~~~~~G~~~~~G~~~~G~G~~~~G~~~~~G~~~~~~~~G~~~~~~G~~~~~G~~~~G~G~~~~G~~~~~G~~~~~~~~G~~~~~~G~~~~~G~~~~G~G~~~~G~~~~~G~~~~~~~~G~~~~~~G~~~~~G~~~~G~G~~~~G~~~~~G~~~~UU*bTU&jEǭݾy~w9R~۴/k_.DJ?[I-w.֊D.y{wf~~fJ9mBwi_~]?GӋo*JW>4d]m G~~K-/{z~Eܔ ߔe_2'MG=3ʟ/B~?"o[<~Toko1+oA)R6 ~b6 B ,o^[9c~\,LO7O~~ U~~s?|~Hl[[wKظL?On  ~p!N  ~Bm [~ԋ[ՋJ֟c'Xpl0w~oi?ށY>H5 9?l+ y~_A[=%~K$8oF*گ֙|~]_mߙ-"^fc[I|z]Kשw~ `)ȥ7`gز߱ غSis\J?GۺSn/?)p\+_>ïT; mā_ .[˻Xsr],Jn8gLNee_5i[o&6V{=QW5Y1ۯh lieX9?,mZCse1D-'ug_uӨ}kvYLD T-l@^Dzl|گP~= TYT7_@OIq{Eaia_5_8/ibFL@Ծ!ɫ/g_~EiK&.m)k@c~EO}[7"vhbM}-oFFyߠ+t/Fě}ò]/u_>ǯiSr~&:lIZ6ٯN<2M'5 aW ŕ/+d3]c;E.v5/t;7 ߭slK+kϼ~Rݹ2 !b]c٫&Z՚q]-v~tXՀlK_=w~SΗԀl W\Q"0sCW͙rzI$j:'s)\/.H:6]Z4 կ~R~”=˱WaӑE#e3KSg *~Z&߈tz{lpc{z rC\a-1]/||y?V'=rdf^=˗/NѼ"~ܯO^x[컴gF?9i}|Lk_ 8q*'մ~I7xt%ނ\D<ۈmoӧϪ}w0k[?-dSSYsjVQW4 [?ϰMS.tXák>J(c+KMT[Rj~J4]][*Wퟑ; %Bm,KXV咹 G~A WOh0YhKź`SٳaC;9Z?WVрKWU ~TgK#mGKTgKU\Ks/7L?y ~>s7x:ұu#4xW?uTb~[ Qf'!^[[(Fߨ켹_*6>%ʧ2{ef_etگOWO`$~+/WW|_~\Z_b~~?&fwz?~[F x~7mWo/N\*;qs+%n7ut>!~Gn-l0RO^U~ N]ÓV51~JٯG *yp9\<Ԁ,ywK[A,g +_ &G~2skyE~Y׌Vdl7Llh%e㲃`5 FFL2Xѵ_twFw;T~S?E֯=E/}/NM7"uߴKg^\W %G9oOW9O/5p:i4&7R̨rb<05K/W(XcČ :~26~] (d39_/ns U֯*~8`zETSOukM]/ܬ_2I/߲bOM<*xBg$nEU8̠U߭,E_8d@~s5J,|v/TyzY;بb}zPV ?;q̟_į^< Hq^,:OM~$~_į3Tm'lAev ߝ'mISf:1T_/%~Eu;}.qua߭nsTH?C._]-W^~BBFt?_r`?+7..K1TOW@ E+|S0xp_ޯײ8oЀDӭWS,C04;RYe-Vt1>`N~R"^ LfI_ܯ͠LJK]O}%N_5-҄W c-^E+Z̼?cj~m5k :B[U~YAlUW#ү !2xPx~2#+y ڞc7eF<!Ķ><>^'t!i~w[+̦XvFĦ`?$;/w…:1o~߷nFX3v?U4!N[.J/*{>ܯ6g+;/m3@e`nU|GU7b3auD8OۗK˲ݵm~w}U'K.U'+~U',7(;=ܮӓ]X=_֖\෥INq /~!w">~`{%~a~+@6daos!aa{\X7rf 5q?ueS'ĽqM5 BX7v\L_܅>L7o,~q<~YrK߳Uvf/K||OZǯ{" Cms㷭oc??~~~~~~w`??͏G~~g/~G??(??x~???Ix~???'????.q/~W/~///~71~h?Ï~<(?????????????wmRpKBD\ ; qF [Y6oK'Vg ~|X/~u vV𫫿>~kߨ<_YO.p ~66 gdmB8N*?_e.~Mc[|i4~+X/bNt~ ~+"j̾~em+k;~KkKer_4ǡ᯷%+Rh~+Z09O ^ݚa1of4 hm>lk?:mhnsm~q(d͗XjU偶=]{aJˆ_چز `Ko8Ov5 %ʮP`l~wj] ȡ~]tyʥKz eEj"ݪIRlyڊ~lG&ܦ ȗZ<m{TM~OTaSx_T^4t~Uڴ@עu%T&TW`Y4z ۭ4 T&]0{V]HzMVCV6=OYK}Кשi#bƶdЇi6$%>OY:2@?-a5HG֩2sfQ~.Z,+@[P!̒ (?Vs5PX (?mVgl>TZ2}aQb$A~"n ==c}}F]Ct&|SXpqebilFc~:?M 瘓ply~ٳ lC,C&LJon(?M2>ьO?սb}>ty9xϝ|U<ƻoSyqoo_Rg4~t YE3z(m'ao_ gf?y~~kn /o_&0dxKӵT8 3%T!3͙svS{M2Ϗw[ZF?JC#ߋ|6w/~*?o~=1~r?K?/?,~X~~G~gWz9We6#b{_3~?^)~S~#x~=_EP?^?~~G0-feh???>?x~OG?[?~~K??^KG?h)2?~WM[bt~q4IqL|N!" ~S/!~o*OOůu/h>ׅZ?C+p[wZmQ//i?}lU9S߸_0͇MT44~/OL K5y=[TWe M)_ׯ.`A;*@1}`?jxieEw_Ҋ lnGf{_.] ӗ1g3H[7:QGaGq>+%Q~!T> /-TG5`!?Y|k<8/0#**{>/-aV=V~eϐ&veM|n?o4_f{XC5ʖ7VŶUMP"i~3DEoB.E+Y?x7ToV= [=!UGC}K3@$Ve/C:rȦҴ)xVo@``fYw_Wb˪I8ye~jV~ { lZwzn'\gUC%1-{"{eSond(N7Cm˞7X5vz*ض ~*Һ ~ ־~Bl]w ¾~,~aeyu+BVfSl]|?9!ll~W/ڸca{z66+_DXïR~~"n - ߦ 0oiR;vf//2{9_jcD~ljB6Dngߛ~~ᇟe~G ?VD~G~~~7;RG?Ï~c?_?g??;~~~~~~~w'7]\Ga 3l9ʉ{a3G>q$~3  ~՟j:̑L\Tln@n~GX!}q6oe[/h*A֦A6}G*>~~~B$]}r?y?~.~k"o~GW7kW|JK{?R;&{Ud/׽d{*,-h0G׬u?/{?~QbrU?){?ά+:آ6U7Bt,~]?#~s ӉIpB~Ê$ 珞u\Tݬ~+ܪ[U~u~K~ڒZW1~0F>/wec\sd}˕ wiJMm5/g 3n366#cuv)0~jryʀ|[Ic9sm)M佟8_MW~qpsu19 v~8Mٽ+3V&}b1)*3SBS]ql,@+U%~&8F[Q;brP/O'OYjE~F.z/嬚]`FU~͕ɚ~Mmv򋅓OLJ8nj?|"G]&t_կ.Vѯ3n25nkk^̺tYM=B֏IRϏmm'/k~AOfMU9#5/i?1Ѵ|eNrzT)JW5E0X77IB?OϨ󯂳aV_%"sg\އU&H&zʧȞeRuK`}}O9_~:%0>ꁫH 'G^Nv?%l5y~YBV :a~3BOM;V^LԢp̓g_83~%d"{IXܯx,{ \]ΕW,h>71O蚏P6~/_]t$j6z6%}U~r w fѯiK:s9FW;?ǐ=)̯9a/jVyyʯ՟ܣ=:] n^ו8dSNfQtqAu:O:=ѯz~S74o +Wފj5Ws3:_2w+?{?y0q~beϫE2t =÷jm_9iv~Ϸ//eue;yZ䧦%~7^'WWu~dW_<㦆vd=j9Ɵi<֯풮-Sބx_*uQq Q%'/Jo'#fykpn$¦>OVr:+qJwO䗷~ū_TF胪.n[X\r"?95~ (/M~Zoj_;̜+7N'd}a~^)K)gE{^M}Ӟtd~bK_}A@Ni[n1x??ox*N_նsɓ ݥvd_5{˙T75i>= 1ٰ/`9_9Yb}(U{z3X}O|_<&toAuO'mΟOuI/]4ApwUEezI?PnSFKϟO#$ |'xwyyοW\y;ml\vY- N~0gӦQly~yM,[^c_:Rk[׸mX_zF"@\+bg__d>O!K/q?ί%K }7YM~~Y96~.~ӹo0ͬxZ?~>Iϙ[vx~_޿ms߿ݞ߶g:>^??.\/3[3>.0Wl3q\oa4ԓ]okZߦ{۹UP %O;W6Un~LKyᾄߦ[rioƕn1fJWZ8|fw~Do~T[2Q7lzq9_i8Eȼ~S7OdBW~Pn ?]A2ZwAs \m ~@oysW7rf-|j%.WdJW+?~_of|EoN|Y׵DWM&r+nm1()5·"y?H尒f'_έ% Kn5̎/zS?~NtY]P=;}S3J[EqO_W3fmo[ٵBF?n/;}Ǜi~trֻuה}/eO^O5yge}fIIm7ǯ§+}ېLt ~M~jl_NPvB~ի6X~,|/T Nl߷w[:/]'_7iwo*ɯs'v>uίnr ѭěy|?gλ;ϐ՛j&/|iׯ^ZQ_r(N>,?O}u`52ǯ\ j~-/jܿ?=B8s\ Qp| zyR6cKwKZڬYo9X{ʯȦO7k L:r)jt0Θ">_v{W~ib/`b j,6 'dž'@BӾӟTݾXtI}s'pftc6E2PՍsf߭Ջ7R.jiιu~D&W 97 wf)3ՕT˥ӜWҜͩWi j )tIluO?0'Hίͦꂕ@tc ~c9j KM׈Lu*:_N5Cإ/,Z)S~ίN,BPO4gK:p5G7&fj5ņ~M.Չ9ʯ,USr2|m{zF?j*WEl~.uuk7S~XW((_/4lYK:pK|8ҩŷ~Tt~QU-/~ۭk5եQ'G풍6w|x֌:8ڿlv}|.va%9ctafNV/ֽd 'c_l װ zᴬvV_!1eUnw^fjIoLv0rwXf~S,vZ6f:*?yoB\)_/ivKk(qG[Cy~lM7+:tٴƼ -s+5?T3I}mߵ ~׳ c gո:/Skd0e 'T>E#Wp4xLV_ݒ{',{lY^Yhꃷ2D42 5ޱ0@oW=cB;7Ϧk|ȶciy]OGWk}A׼/o;7/o|5wڶ7\t#4wEvDjEzf8t769$lۿnjS:BJ ef^矘gUU/535]ݛ_tWNղkr,RY5Wv9WtV?]-I߿ڭ7/6Ll+_*)mү^h_-_+΃WN*աµy4Mx X FXu~~3x68dޕm23m}Y!]D4rbU3?\W&Ky}ˊY ^øE7",;?4Vιwu=V_M92M3l:?4VT.%5ZĽbi{0=@6Ňp KKywS:ܯ:/KAZW‰3gM5/)?+J: نn&BO-_:4~7qfy~Kꍻ%jv\sZ.3N.NM1$ͯ\kMM/xLw_)ݺrxp Ǧw~Ɲ>u/.AHĖĒ׎EmSkP/5.~1~%_nI5~UWn${~%y^U3_~tmo_yNG_!_y~Ho9Ho|vm+Wu tqeǣ~+,KZl,pyoe):/mlezn(Z?_&[8 {}SL3o/}کuv/=ίS*_2ϛ+_嗫t,?͓]O-پkK˓QpJ7j旞/j7N_냵@Njz]VrۘK&|_=R찾K'/Id?s紽ݲP]i}_@;l/?6//dM)ǭ1խ AB@k;HƓ#ir)\/L~ɴ_:OvX9ox񸣶w&tj*%A;o|~o4aw،/$B!3a闵~jcQN_X}_(Ư+~n[P)QQH|~}v9& *YW:?9^8jq,4d^u`og5ʒ(@|Rbi ,>'T71TF>2Hv 7T'>gn_Ws`àkA7MUsZ":gu%~ԫs?o+jDK4X9k2X~ee։q-Z33XtU&?/~uK}_m/L=q0]Gn?Ưh`?M~ŇZ}= KTQ{O^W~_X<%c~EP?~]8| |c"lս= ϟ>C~ix#`įq?KK\~~~':[RL%G_yɳ_>OW5rk8v9ss/iag]6KE=yfǝY.^xo@F/}{?1~G҇0E}m_"tqKRwygr/UCZ|W?9~/Z / {?p:gr%󈣧vίT'O@m q3TZ<q?^w.ؓ_~v7M '^w ۏ?1U3$q k\n]Vš~/]=ᰡW/9iOŠEs4yدLLkyW܏?/zkCrjxbO_W}_(4g ~ ~f?|~~ ?M.~/d2rīޜ G^XgS̑)01~~qxs^gg9E?sؼ{gi~*6m}"u?7܁T؝3Wp7g@o"RV V0~U0~mY;^ו~aB9˵ťw.kܯhܵ~lR+j{NqUR Ս-4[3>=x*a2门] /V*L>O>ko`_b3WPEiANV_" '~759@~uny򗪛jPr[CBrQLch"uRY.^&c~i>׸7Wv'UW^Я[[3y`UiQ5~*?98~/R5z?۟~_yUx_[f/RMiG~XSv[Xk/~~{-lJa-s fgRf+-kj1~OI{w~Kǟ/Y_~DpÿAܐ@T痬Ow߾俎WYeu.~0$Z>-+Br35S?n%_77~K5ʅ+r!;q޳Y S⇄~V?9 KҾ  WUK,KDO-;`/r!l?//4TW*_i_,~ 'HlۏhK3nhn5z[ԯ=U^BɲίvοX)fįnֽX]+g[<_u~G%+4>S8y_uss[NW%/}K~Wwsz@w}Ucl-&)]k3d_ts{UZu~ώo$)Ko}7c~AWWis o~v?E7ϳ/+6~#h/0_WOX>WWv~ߠF*t?47 焿c{1aP_ I1)"x~b, q5p?&bWSsT,vX 25cFϯ}B.t9f"k7Iǟ!o_49cO_\s+*+~bxWnNdzcKB}Wb*%y>\y To?gI+ ~UsyyS~}LwZҖw~ZfO܋bgk+egvjvN''_s#h9^n:֥:z+ k,(w+"󍜥鬂>w oq]'?k/ [G["WHzcN?Ioq#ת4}WW㌛Nof$[tI5-tk9GGoAD׆Fv]f1o}N׼\ޚ1em׌k?M~!~"6D׉;NKJ?_~ym?P?G?o!Q߁Q2~ߡ~r-o׾N闄mcʐ,V]& ٌ/4Q7#}9G 99}j~*?_*y#<]ۯuIE?C /pdNݧǃo}g g"K: Z()kTݴt~՝;ߗG6~e;RXȋڱym;= xiN*/Otl>)ih$ccZ{2tV^k 꿦ʱ|eV{啧J'v'6n~~>^#{(Q2sae5RG&su!te2_o/k}ݡkgGrxU-:~IW5~'׌TiSq@<~rb(zgZgK&5 t*dt~~O7~_07 ;?oZp)xQ/Lܷ.!٥˟W9I0Eso~_* |F^ү6~b_ka_9/o<W+[WĢ'[Q_zaD]y~3o4MTΜOj_m8+No~V.x9\\ݯ^>Yo7+v_]<_pnd\eu~Zti^~,(a9~U/(ڕ>~=,@8ȯvM 7?7)_݊ NAze_)/+-Uy rQ\}\O>'X6~Wc/JC=}U7_~ܯrzܗd_7^u~W].+ W9UlO! De4K`{S_ OLE~y]WL_z>{ϼKO~o\d%BS/ 9-fjyy֯I]\8k[fR/A:0y-h"A9o\uO^n/ocoiC?(Ki??AN'>Ӝ5~?`1|V~~G~~~~G~G~~~~G~~~~~G~~~~~~G~~~~~G~~~~G~~~G~~~~G~G~~~~G~~~~~G~~~~~~G~~~~~G~~~~G~~~G~~~~G~G~~~~G~~~~~G~~~~~~G~~~~~G~~~~G~~~G~~~~G~G~~~~G~~~~~G~~~~~~G~~~~~G~~~~G~~~G~~~~G~G~~~~G~~~~~G~~~~~~G~!<}mDu? $$Ifl!vh5 5 5 #v :V l40#,5 alf4ytj$$Ifl!vh5 5 5 #v :V l40#,5 alf4ytj$$Ifl!vh5 5 5 #v :V l40#,5 alf4ytj$$Ifl!vh5 5 5 #v :V l40#,5 alf4ytj$$Ifl!vh5 5 5 #v :V l40#,5 alf4ytj$$Ifl!vh5 5 5 #v :V l40#,5 alf4ytj$$Ifl!vh5 5 5 #v :V l40#,5 alf4ytj$$Ifl!vh5##v#:V l40#5#/ alf4yt$$Ifl!vh5O55555#vO#v#v#v#v#v:V l40p#,5O55555alf4$$Ifl!vh5O55555#vO#v#v#v#v#v:V l40p#,5O55555alf4$$Ifl!vh5O55555#vO#v#v#v#v#v:V l40p#,5O55555alf4$$Ifl!vh5O55555#vO#v#v#v#v#v:V l40p#,5O55555alf4$$Ifl!vh5O55555#vO#v#v#v#v#v:V l40p#,5O55555alf4$$Ifl!vh5O55555#vO#v#v#v#v#v:V l40p#,5O55555alf4$$Ifl!vh5O55555#vO#v#v#v#v#v:V l40p#,5O55555alf4$$Ifl!vh5O55555#vO#v#v#v#v#v:V l40p#,5O55555alf4$$Ifl!vh5p##vp#:V l40p#5p#/ alf4$$If!vh5M5n5!#vM#vn#v!:V l40#++5M5n5!f4$$If!vh5M5n5555#vM#vn#v#v:V l40#++5M5n55f4$$If!vh5M5n5555#vM#vn#v#v:V l0#5M5n55$$If!vh5M5n5555#vM#vn#v#v:V l0#5M5n55$$If!vh5M5n5555#vM#vn#v#v:V l0#5M5n55$$If!vh5M5n5555#vM#vn#v#v:V l0#5M5n55$$If!vh5##v#:V l40#5#/ f4$$Ifl!vh5 5 5 #v :V l40#,5 alf4yt:$$Ifl!vh5 5 5 #v :V l40#,5 alf4yt:$$Ifl!vh5 5 5 #v :V l40#,5 alf4yt:$$Ifl!vh5 5 5 #v :V l40#,5 alf4yt:$$Ifl!vh5 5 5 #v :V l40#,5 alf4yt:$$Ifl!vh5 5 5 #v :V l40#,5 alf4yt:$$Ifl!vh5 5 5 #v :V l40#,5 alf4yt:$$Ifl!vh5 5 5 #v :V l40#,5 alf4yt:$$Ifl!vh5 5 5 #v :V l40#,5 alf4yt:$$Ifl!vh5 5 5 #v :V l40#,5 alf4yt:$$Ifl!vh5 5 5 #v :V l40#,5 alf4yt:$$Ifl!vh5 5 5 #v :V l40#,5 alf4yt:$$Ifl!vh5 5 5 #v :V l40#,5 alf4yt:$$Ifl!vh5 5 5 #v :V l40#,5 alf4yt:$$Ifl!vh5##v#:V l40#5#/ alf4yt:$$Ifl!vh5##v#:V l40,5#alf4ytk$$Ifl!vh5 5 5 #v :V l40,5 alf4ytk$$Ifl!vh5 555@5#v #v#v@#v:V l40,5 55@5alf4p2ytk$$Ifl!vh5##v#:V l40,5#alf4ytk$$Ifl!vh5 555@5#v #v#v@#v:V l40,5 55@5alf4p2ytk$$Ifl!vh5##v#:V l40,5#alf4ytk$$Ifl!vh5 555@5#v #v#v@#v:V l40,5 55@5alf4p2ytk$$Ifl!vh5 555@5#v #v#v@#v:V l40,5 55@5alf4p2ytk$$Ifl!vh5##v#:V l40,5#alf4ytk$$Ifl!vh5 5 5 #v :V l40,5 alf4ytk$$Ifl!vh5 555@5#v #v#v@#v:V l40,5 55@5alf4p2ytk$$Ifl!vh5##v#:V l40,5#alf4ytk$$Ifl!vh5 555@5#v #v#v@#v:V l40,5 55@5alf4p2ytk$$Ifl!vh5 555@5#v #v#v@#v:V l40,5 55@5alf4p2ytk$$Ifl!vh5##v#:V l40,5#alf4ytk$$Ifl!vh5 555@5#v #v#v@#v:V l40,5 55@5alf4p2ytk$$Ifl!vh5 555@5#v #v#v@#v:V l40,5 55@5alf4p2ytk$$Ifl!vh5##v#:V l405#/ alf4ytk$$Ifq!vh5a5#va#v:V l440W$+5a5aqf4$$Ifq!vh5a5}5~5}5~#va#v}#v~#v}#v~:V l440W$+5a5}5~5}5~aqf4w$$Ifq!vh5W$#vW$:V l40W$5W$aqf4$$Ifq!vh5a5}5~5}5~#va#v}#v~#v}#v~:V l0W$5a5}5~5}5~aq$$Ifq!vh5a5}5~5}5~#va#v}#v~#v}#v~:V l0W$5a5}5~5}5~aq$$Ifq!vh5a5}5~5}5~#va#v}#v~#v}#v~:V l0W$5a5}5~5}5~aq$$Ifq!vh5a5}5~5}5~#va#v}#v~#v}#v~:V l0W$5a5}5~5}5~aq$$Ifq!vh5a5}5~5}5~#va#v}#v~#v}#v~:V l0W$5a5}5~5}5~aq$$Ifq!vh5a5}5~5}5~#va#v}#v~#v}#v~:V l0W$5a5}5~5}5~aq$$Ifq!vh5a5}5~5}5~#va#v}#v~#v}#v~:V l0W$5a5}5~5}5~aqw$$Ifq!vh5W$#vW$:V l40W$5W$aqf4$$Ifq!vh5a5}5~5}5~#va#v}#v~#v}#v~:V l0W$5a5}5~5}5~aqw$$Ifq!vh5W$#vW$:V l40W$5W$aqf4$$Ifq!vh5a5}5~5}5~#va#v}#v~#v}#v~:V l0W$5a5}5~5}5~aq$$Ifq!vh5a5}5~5}5~#va#v}#v~#v}#v~:V l0W$5a5}5~5}5~aq$$Ifq!vh5a5}5~5}5~#va#v}#v~#v}#v~:V l0W$5a5}5~5}5~aq$$Ifq!vh5a5}5~5}5~#va#v}#v~#v}#v~:V l0W$5a5}5~5}5~aq$$Ifq!vh5a5}5~5}5~#va#v}#v~#v}#v~:V l0W$5a5}5~5}5~aqw$$Ifq!vh5W$#vW$:V l40W$5W$aqf4$$Ifq!vh5a5}5~5}5~#va#v}#v~#v}#v~:V l0W$5a5}5~5}5~aq$$Ifq!vh5a5}5~5}5~#va#v}#v~#v}#v~:V l0W$5a5}5~5}5~aq$$Ifq!vh5a5}5~5}5~#va#v}#v~#v}#v~:V l0W$5a5}5~5}5~aq$$Ifq!vh5a5}5~5}5~#va#v}#v~#v}#v~:V l0W$5a5}5~5}5~aqw$$Ifq!vh5W$#vW$:V l40W$5W$aqf4$$Ifq!vh5a5}5~5}5~#va#v}#v~#v}#v~:V l0W$5a5}5~5}5~aq$$Ifq!vh5a5}5~5}5~#va#v}#v~#v}#v~:V l0W$5a5}5~5}5~aq$$Ifq!vh5a5}5~5}5~#va#v}#v~#v}#v~:V l0W$5a5}5~5}5~aq$$Ifq!vh5a5}5~5}5~#va#v}#v~#v}#v~:V l0W$5a5}5~5}5~aq$$Ifq!vh5a5}5~5}5~#va#v}#v~#v}#v~:V l0W$5a5}5~5}5~aqw$$Ifq!vh5W$#vW$:V l40W$5W$aqf4$$Ifq!vh5a5}5~5}5~#va#v}#v~#v}#v~:V l0W$5a5}5~5}5~aq$$Ifq!vh5a5}5~5}5~#va#v}#v~#v}#v~:V l0W$5a5}5~5}5~aq$$Ifq!vh5a5}5~5}5~#va#v}#v~#v}#v~:V l0W$5a5}5~5}5~aqw$$Ifq!vh5W$#vW$:V l40W$5W$aqf4$$Ifq!vh5a5}5~5}5~#va#v}#v~#v}#v~:V l0W$5a5}5~5}5~aq$$Ifq!vh5a5}5~5}5~#va#v}#v~#v}#v~:V l0W$5a5}5~5}5~aqw$$Ifq!vh5W$#vW$:V l40W$5W$aqf4$$Ifq!vh5a5}5~5}5~#va#v}#v~#v}#v~:V l0W$5a5}5~5}5~aqw$$Ifq!vh5W$#vW$:V l40W$5W$aqf4$$Ifq!vh5a5}5~5}5~#va#v}#v~#v}#v~:V l0W$5a5}5~5}5~aq$$Ifq!vh5a5}5~5}5~#va#v}#v~#v}#v~:V l0W$5a5}5~5}5~aq$$Ifq!vh5a5}5~5}5~#va#v}#v~#v}#v~:V l0W$5a5}5~5}5~aq$$Ifq!vh5a5}5~5}5~#va#v}#v~#v}#v~:V l0W$5a5}5~5}5~aq$$Ifq!vh5a5}5~5}5~#va#v}#v~#v}#v~:V l0W$5a5}5~5}5~aq$$Ifq!vh5a5}5~5}5~#va#v}#v~#v}#v~:V l0W$5a5}5~5}5~aqw$$Ifq!vh5W$#vW$:V l40W$5W$aqf4$$Ifq!vh5a5}5~5}5~#va#v}#v~#v}#v~:V l0W$5a5}5~5}5~aqw$$Ifq!vh5W$#vW$:V l40W$5W$aqf4$$Ifq!vh5a5}5~5}5~#va#v}#v~#v}#v~:V l0W$5a5}5~5}5~aq$$Ifq!vh5a5}5~5}5~#va#v}#v~#v}#v~:V l0W$5a5}5~5}5~aq$$If!vh55#v#v:V 44 ,55/ 4 f4p$$If!vh55j 5j #v#vj :V 44 ,55j /  / 4 f4pu$$If!vh5i"#vi":V 4  5i"/ 4 f4p $$If!vh55j 5j #v#vj :V 4 ,55j / /  4 f4pu$$If!vh5i"#vi":V 4  5i"/ 4 f4p $$If!vh55j 5j #v#vj :V 4 ,55j / / 4 f4p$$If!vh55j 5j #v#vj :V 4 ,55j / 4 f4p$$If!vh55j 5j #v#vj :V 4 ,55j / 4 f4p$$If!vh55j 5j #v#vj :V 4 ,55j / 4 f4p$$If!vh55j 5j #v#vj :V 4 ,55j / 4 f4p$$If!vh55j 5j #v#vj :V 4 ,55j / 4 f4p$$If!vh5i"#vi":V 4  5i"/ /  4 f4p $$If!vh55j 5j #v#vj :V 4 ,55j / 4 f4p$$If!vh55j 5j #v#vj :V 4 ,55j / 4 f4py$$If!vh5i"#vi":V 4  5i"/ 4 f4p $$If!vh55j 5j #v#vj :V 4 ,55j / 4 f4p$$If!vh55j 5j #v#vj :V 4 ,55j / 4 f4p$$If!vh5i"#vi":V 4  5i"/ /  4 f4p $$If!vh55j 5j #v#vj :V 4 ,55j / 4 f4p$$If]!vh5v 5#vv #v:V l4O#,5v 5/ /  / a]$$If]!vh5v 5)5X5X#vv #v)#vX:V l4O#,5v 5)5X/ /  / a] $$If]!vh5v 55h55_55_#vv #v#vh#v#v_#v#v_:V l4O#,5v 55h55_55_/ / / /  a]l$$If]!vh5O##vO#:V l4+O#,5O#/ / a] $$If]!vh5v 55h55_55_#vv #v#vh#v#v_#v#v_:V l4O#,5v 55h55_55_/ / / /  a]l$$If]!vh5O##vO#:V l4%O#,5O#/ / a] $$If]!vh5v 55h55_55_#vv #v#vh#v#v_#v#v_:V l4O#,5v 55h55_55_/ / / /  a] $$If]!vh5v 55h55_55_#vv #v#vh#v#v_#v#v_:V l4O#,5v 55h55_55_/ / / /  a]l$$If]!vh5O##vO#:V l4O#,5O#/ / a] $$If]!vh5v 55h55_55_#vv #v#vh#v#v_#v#v_:V l4O#,5v 55h55_55_/ / / /  a]l$$If]!vh5O##vO#:V l4O#,5O#/ / a] $$If]!vh5v 55h55_55_#vv #v#vh#v#v_#v#v_:V l4O#,5v 55h55_55_/ / / /  a] $$If]!vh5v 55h55_55_#vv #v#vh#v#v_#v#v_:V l4O#,5v 55h55_55_/ / / /  a] $$If]!vh5v 55h55_55_#vv #v#vh#v#v_#v#v_:V l4O#,5v 55h55_55_/ / / /  a] $$If]!vh5v 55h55_55_#vv #v#vh#v#v_#v#v_:V l4O#,5v 55h55_55_/ / / /  a] $$If]!vh5v 55h55_55_#vv #v#vh#v#v_#v#v_:V l4O#,5v 55h55_55_/ / / /  a]l$$If]!vh5O##vO#:V l4O#,5O#/ / a] $$If]!vh5v 55h55_55_#vv #v#vh#v#v_#v#v_:V l4O#,5v 55h55_55_/ / / /  a]l$$If]!vh5O##vO#:V l4O#,5O#/ / a] $$If]!vh5v 55h55_55_#vv #v#vh#v#v_#v#v_:V l4O#,5v 55h55_55_/ / / /  a]l$$If]!vh5O##vO#:V l4OO#,5O#/ / a] $$If]!vh5v 55h55_55_#vv #v#vh#v#v_#v#v_:V l4O#,5v 55h55_55_/ / / /  a] $$If]!vh5v 55h55_55_#vv #v#vh#v#v_#v#v_:V l4O#,5v 55h55_55_/ / / /  a]l$$If]!vh5O##vO#:V l40O#,5O#/ / a] $$If]!vh5v 55h55_55_#vv #v#vh#v#v_#v#v_:V l4O#,5v 55h55_55_/ / / /  a] $$If]!vh5v 55h55_55_#vv #v#vh#v#v_#v#v_:V l4 O#,5v 55h55_55_/ / / /  a] $$If]!vh5v 55h55_55_#vv #v#vh#v#v_#v#v_:V l4O#,5v 55h55_55_/ / / /  a] $$If]!vh5v 55h55_55_#vv #v#vh#v#v_#v#v_:V l4O#,5v 55h55_55_/ / / /  a]l$$If]!vh5O##vO#:V l4O#,5O#/ / a] $$If]!vh5v 55h55_55_#vv #v#vh#v#v_#v#v_:V l4O#,5v 55h55_55_/ / / /  a]$$If!vh55555#v#v#v#v:V l t065555$$If!vh55555#v#v#v#v:V l t065555$$If!vh55555#v#v#v#v:V l4 t06+5555$$If!vh55555#v#v#v#v:V l4 t06+5555Dd  + >  # A""g`<7kRD4Jٺv@=Ѻg`<7kRD4JT@ `*8x_j^LJaIA|4Q.|iQ/Ut 3&#h. z墹(1m$R E)# @Qg<  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ\]^_`abcdefghijklmnopqrstuvwxyz{|}~URoot Entry FPڅ{Data [:2WordDocument uObjectPoolw{Pڅ{_1407563970 Fw{w{Ole 1TableCompObjh   FMicrosoft Word Picture MSWordDocWord.Picture.89q Oh+'0L8     ,4<D [(@(NormalCJmH <A@<Default Paragraph Font  l,b$R"ȃfm @n( t 6   AB S  ?h. t@o`@GTimes New Roman5Symbol3& Arial"hGG&!r0 David L. WoodwardDavid L. WoodwardObjInfo OlePres000$WordDocument ySummaryInformation( G bjbjَ y] YYYmoooooo$^RnY7"YYYmMmmmY mYmmmmm @-6yc m  jUmHN N!x!"x!#"$"%nmR"ȃfPNG  IHDR  1ogAMAPLTEٟ pHYsN)6 IDATx^~kU!*0L)SDA(([F@ J"rHF )bH6p ,VxZ8B\/̜>y"ߜsf/;!9{x>) @v APAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPA$yv9!LVYq1e)76wY.Dza/H|ǚ6I}tw E)wv/4J_ԷE.]TYqIy6Է5uR\V6a諴sn#U}Hn=7>\Y!F7oqX}oF*Է Q]APQsmܖvSBiԷN>TS.Zo=h}woqq}$6A}|ԷbdѱX5A}h7dԷ?.WW'RnZuͪ^'gh_]_³Z5:U>SQ߄Res3V-쟠jxJ2gzxqh#F}}x"Jqwػ7u( _)'@TqbP}Ɛ19}7i7Ri<ye"j>ᢝ&.ΨE '#3^]ߔd«׾>f_wUD} +6}5i_zWx\N%Y_W?)/d vLzꓭ0]EäQ?stnGv렾qzv}SժNݷoƬp~f舋Rψ͢{M}/B>SɣϵB*ɝM>Tfw/,]2P1=D"-Θ>tmTůA?l>v[ɮշ }M[*?׋{j$ S^jOX)"} էa ~Rէrv׽s>nmcL}u}>5TjoxQ}OtԨY߻\7zOTZko}Ҩ5*3~NoeġGhTQZW\/OFRg2;~=zs>@}"8'".ZGtHåCzP5N}}klG}gy=Dss|mkֽ>]t|XL곶c+5KGe7]ᡷB +}O2o{_D g13jsk>oy&[]uAk*_fZ^5:x5cgwWF_+dU"3f~ Y8w9rO6lƓI)@Ө}vPY٘vԚ!{d*KUz]ڹErDJ+}jg-Oo$}] KPQ9pLpBN,J>z|LXk)ĤO.Řb(wJ_'=Q["ӧJۣD/s+=P AVZrqns *)!wVfb'{~(T ~j+CqF\NT0u[>>,DOsYLpwDo2?sMMI[VVy2⺛q]NXEdVU%6}ݭp/iDx7eG݄nʎc"*})_TĦd8LLS1Ƥo42b\bWܾZx$2bW޾6;QPe&LvO&*}ijA5σq4p0LC"*}FϗPAԷb1GD7*_M imyofPN، Ky}ܒ>Q\F5R>g} o:+ {HK_]{wo#-}_TE:N dHC_ds" }%ς "}ٷ`&}L}L}A} 68eI" }=!'dAo>ꃠ>⛆HC4|EuK|ӱo:"}5!xw=dg߂d/MD1C伎}t]BoDܼ9WM+$!}qۻsIE_M}\ Vô]\DwC6"}*9$`Oby\>/ul:mY$*zs1+}q 7HA_W#}n@:|^닪d}M1:R8E3O-kU*@.aLuGq \} 0rja!S{v!l q|8*`To賃^͓]T륾AWrFtk}UDA^ֳSHZ[@_qQ})z_@gei=hLIT_-[l 15K}2hӬݛnu3Cy>nw@& }SzL̥UY忏q&R'keح&_<"C)Ӝ/wYQH[}Muqč.j[]b;&d ]-Ζw E髵ݵ Pkוֹ'y刊nt#*uJW_gh6\^E=b1?]@_g$ OM)#>C9qDoq 7xMX>]W,yBd̪ϸEVt; s3TRt kg T+.bDW^f>o"f\o:ַĠӮy,>dDOU_ϣ#% MW:u{4fG;}oVKãp>Էgeϙ5Ҭo{1–Z׷>meA(B oOE[6v6ַ*"-UnWd+ۋ.Q}Z*=^ۺZ")5wWB;ZߘFcww75].X[!b{e~-52Ul nzTtc viiPwlt9u feml\Yַ6fЈ1v/fca'>M}TqI~CӛMMH_͊%sEJn}k-I)Ŭo[tXkғc;Ec!}jFY=+Rꟓi`]K/`f}u) n&Z/Gr\cUܭm .ӈVͳ%A ^(_sŶmCQ𩴽.|]}ۚܚcoǐ(MkuMiMzf}rb¬oǺկSC~%MWE_9GI *|4sNէ핾z@9;WESKR ]{Rߕvҗ׮Ġ$դ8څsL>]_9N jNN}S^} uY$gປeM&WtZws|?R5k@_kH)ܵ*=R _ҷutT7R_+~JRH57yI:Kޭ]?4;Bf?x.} cn ^}zx%ۣ3vn8G5X8U_=BF~ro>nޫcե4Φo}|'gͻsRGv_r|'N\h>Sf}ő|'N\hEdi};}BosD/stm }Ui}J_>^6q_&ϑd6_8\.ѧ*.㎞Ѥ|s9}{ƍHQw]EwĂFq>C[_1ϡ:@Mq-Ot }xep:^}ї!m֟f^X?}i-!z}Z}8Hxb[ʧo=i{9}2b{t#JMf) /O\l 3>5cZ bցk2L8蕬v:SWwklWg5Do\OW+DŽ*}Egq΁b/*bP^װR#7_?r+ Ә^n9Q*6{Aڥ}i9iJ_i\VϛQ[wfs6y\ 3j7!Ë\ysD )>/߭o Rhv@ڍV6y l}3ibi3GWs,Ys5yχR܈w{>Y OF e+9CcD_c1D}9RN"G<*؃Elq\D?Q#\ ,=w@̶>; p}A Os}V>;b|s8<W>Re_\uΕ⑷>w!V 9#\GX ԁWH[(aɫ~}%ԧ֕YD$oq } v~aPٍ+eJ-OۉT]-{{[&u@ojvX-6 x㑓ÛߛEh.,VMRs򮶫=Esv.y7V~+o`c>=KפO8l9YM33]R/j%4`7剙N>뺇h.y{)4F)ӥ~+nV}hvl}Mꇘq֯W2^m{WY&]3i†Y߰EU7uOO4u"z;|:luۻurqcOOZ>!h"ֱT9.u.r|E~EЍԧR*O]> 1+!e}*o*VwIk^Ds1pMIk'~=>.G~[Gvߓ~viҪ;g[oǫGo'5+}訚`\dJYnAS+u#*rE_uT[`@_ +}Y~MkkFOܷwTdkBjD̯V}ވA*a,-Z߼'Go 82oyS 4[w8ٶձfg7~Fߔ}X|}BT.#tMUZSdoGA,[ϽM{FXyZuKyk{O[cXy&MƯ?mYb)y}ek٬//E_1H147˲l>*7sBũ=r>S]髮*.8q{MK=tW>Veչ^5ήE_mp',a^yKi<;eY_WYe7HQ+֧]|a&}[H{Y}"ש.ڻ6}sk=t]jí~&HKE_w羱g*}Z"${'7uTJ}j>p5< >>՟+Ŕk}jA!J.?>YqeZ_DxzX=4⢋moR_~fc{lt]כrf=eQ7Qa IDATJ>~ Eiw}]ɢ790 ŭO^b0++}լ>y?0v }AѨJ2>^_eX=@uߴFDޗ<٫Ͽ+WI&y51JQovv7Ne]xBpW,!FToDUTS^_0ŝ E =V_I<ͭnr!l @_w]ԓ\2Cӕo]U\.tQRV,;9@_%#Y{FXXU7_{ҏqTVJЖ<\Ǧ|C5WJu2uTYZsʮocj~}Z_~ZXnQɱBߜ*e0EU*?jeBeZ>,mnoI>җrFevN=ЮS;Ͻ?T ku.͵>Y' TY^obo:Ol܋G>X_/6/M2YZ٘))Jz^w-3ש كG* &O\tݠ-]_wK\)q}Tӥ2 יߞo|*OHt}b:$3qtig~!zoY|dHK }dTc4ooK;گr@_呖FA ;>YkVu8QP%7jy1+{u(f~AfZWG?V_i o gKX>v?R_-^U);7H:#kA+g{[Ͳݬy#-N*4߂9ri!>rx`gPl ԭkG{W&έݥ#f/<GZ=[8@땾B\A5}4bnß9:n}7l*Oǚ}m}{ZŚ/PMm=:ķZqZ[:dz9Xs[j#"-jw.RS/Lg?P8I_ch=tFbA}5.sN}^X ^Nۂ8}OmNҗ_nY8W8}ּZsn=NUyWmذsG 3ӡvk \}fǀ౞5[bs6@譾yK0mO_5::Ļ}\5dQsnՕiᜮ/m.4XfP6R;Y}.7^k5j)}[*K'\.{󐢷\݇kma!ergWRͦ?inxH١&G}޾( -szg\s[?ٖ-\]7Aޟ`{@b 4jBzl?=0۫Xi{>Kůj~}O]Q]1;gMs n] 1XezO!5f}C@1=[y5OHv}l}mp|6ּs}l}浻T^^и6dQ>#4K\F%ΣMKߟܿTe#(-;jhyBַeGYpwQ[ve 9DYdfDzVi뻉u]f2t黝{lg5+B_{̯ךC0C9TG(5K{W5dz̯0HS^^% 4#cͩ}oW1 q,;}E鎸'ZQ&z0  dAwh}[8~`Bƹ*83vy&ՇWmHٽOiܹp@eǚS-yk:t1kIS_;E+dg10:r@\e)KTG*To9YVq3(4:gSU 樊5[rdzg^ՠ+諓ԧ h:(j5/ 'W8b ];Oך-j2};'@$EVZXf wſi Մ(Ϻw0W;$l-㚧wեR)}vU SR*ToӣNQ_>z֫%iRg M5yrΧ 7U@\C|Գ5ә_?O1_M5R9pV+Gyk=Ce{=A6gT(ވxǷw{.HY>C.k0 TGJuq)>CGzlZe cwkdoJeG'+ݤo=.jFnFo_F .C\ħQ+/~7[&h}ŴA:sW(}:MX#C%E~zѽM枮dECdPdw :J*͝r#| >? .4"P|{zBK .O\ٳLwPa1DGMnyϲÑ'RW_S^VB/  %}"1쎠{޲fiOrtW-@W}֧斣QQS ^V}껷 *s;7p{Ẹ3]76X>ݻLBNN}ݲvVZxX[)Aj[x~i/iXrĢRo'ަڛl}׼|([6EDߥ(7MaYЯyMu Gyf͕k]s>ꔇmC^g\ߚ*O\Gc9Kˣoy>"nէѥ1_uߵȺFtGwPO[r-sfnG(;*C '9 4&}GR~;_60E_ngrrѥ&} Ub* &D횕*<HHԧstUڞyoQ%2U0%RY5S7MLX̀\M>T7Bf}Wo=cc*6:i}zB}U@zmaJto:k \5/R%kt<^/§'ʀ|^>eR՗+(22loϛ#+D_|qT+1 'CWOJ۩ #d2 |hZD)RKA4RU-qʹmە\v0Նf!EvV,aeo?d_zonnCu\r[[ݶ>Ay_>em^N+}Ũְ,_tg"?zqDǽT޶aҗ+}[OO -rZ_n}z9sOt Kg_V[@Ѽj=찘>l%~x{Rtx*+Fv}ϯo.[ %+SkK5ޣ>O {>S=~xk9On^B_;1g׼qWgl<~OYynl>煒B^Z_o> 2z.uGv]yggT;//48=VGf_q~atj-!T9p/^B>'p ,;·NtQ}Jw/t#X;?r+DZIg3SWX9q\Kmܐ78 =\%ȕ!Wi!5}pϭo6d/3HU_sGs|{r}xrI5yWQIՇ?%fSM}y\qqnWD}^^^ɩ!BSXL'E}9t)W`~; kT}]okcǸ8iո>WS!쎨S P=af׮>O/S+f@}~\6>/ J}XֳkgJ[_6FoZ{M}~!gUԗh7ge#9:Kc'MPm$:-&}Ŷs>"Xu6g eBr*V">~Yk"aNm\D5}}v!~b}/a&}Nm_~Lb+|Ԏ`Pߚʱ[93QwormjonVtYYgAouKn8GoЛe?kVlTvj~kdrqk ;-C(Qly6 }~רcM_Nu䪺PA۶A}֪uKj ({ϿJ_7mոҿzuC9 }]#`}޾5Be2lHܠqŵ~Sz[}٢Yrj.}b@'JєdWm);Чo>W-K^nI=Y[ʎNf;'[mŞ(4BE$>"^KX[3g|L/}ޗXkvn*a/K_dنvG$FôMc =#uW^C SelM&Q$A'ʯ?^_>NOC6]?8AI}kJKrQV Zxx(K^>21bWkdyu{K }zϤo|>5+oN|U];U "ToGT_bPWWЧt#*Bߜy؋]ܠB}D7rsD6 n) aзzxW#R_{jX%6nзJ}n}X>4 aW)Vsk3#EzSRst J\j>Uh:>=%pK\Y`|@U YyX֋8f{;Vd~LA9ݼXjm=e&,`B8 ՈBgdҠHAs-~=kFe~aU3|!zf{BŌQ,]qNR_9| eG1wT6ƜGB`}CTc'}͏K.m"Vߣ }Ud9@ͅ qSE_e֧S7-kk2=z75}u>ҷA.*}seaZP}U~lk5V}*FaXN>=)6GB7rmF>D'|j=;}a!}?40z>=<20;޽8 GzUv9A|>cDQZu&ُB_mWNEŬ;R't\-}kjK_;%oFhOU_zxscjg_,^jX>X*1zLġO.D7P<9F~γG{#{4}jL];u"wK7g9}.*[_3M-Z]V80>v_>fK@}rο{sVEGƠo^GP^oT:j$ZGO.(i \c=&`%8qg]ƦmuSag>(QeW?SɠEWj YG|ɝlMjp-`z4Tep%`f} F0G@:IF_wk0kq6<1稆L:nnp,s?-IV_o'dt`Aw$&Z♕E[35~ ObXk֒oX}r_qC.gl7&~]}_+w_[NȀb'+OԷf}wQA }Q>=$1.ꓷX,>]\cb75A}.eq3BD}fךB\knP \knPKW 2FoHa@"էcRNjϒ%,YB}N)}se%KKM}nXH}Mx,>/?ƬϽꃠ>ꃠ>ꃠ>ꃠ>ꃠ>ꃠ>ꃠ>H1\ A}A}A}A}a :"mꃠ>"Dr Xm>ꃠ>`G%SD}l%ۦ>: EC IDATAPAPAP}JXt PAԇ@}A}A}FAΕ%}ٷH5-Y"&}kCD_7f޹ZġϳRġOe(Z7x⋗(Rٷ(m\SDOm">sUZ_~l'}mɅLOWOE#*d}sJ5>*[BΒ\ܻ]KQqm\}K@?ub߹[4e~[7.ߩV!KZgU|T'Y~Ut $58U_\/L}Wm ]Қp뮡Zie~g[ uR53]gs:&=Vtsnh'ko(:ؗTD}M3tʎ>zAR!ݏ)Pޒ w]LrN);O_{u*3L)dz.4+)E gxF/4}걊Tq>M~Qg3mUѦSv4Ceu'tj~g3Wt ._"޳n"HfNgD />^0^ LOgɄLOg}:UّsهbυlҪ8^4ꩶ-q>a(;NWIUOJ[j$2=E+T/Qs e)\+cH8C{1 }IE З9tXyM&q>}bil s>_0Qޒ8MIkp0ҥ>oF%gĻ#`;nw>Oҙ_M}&_-h9Uvtg^ek@3xC^R 鲃L@ R} Y;YRƯ>+F>!*]E}B">B_9>"JAH}f>o'^7p7Ag 13 $,3A}A}EGC} 7`ꃠ>ꃨ%/DM} "X#.&>3A}A}f3A}A} @ԇ@}  88 A}A}A}R BPDQ@p_hYt PAPEH}Ap  qh!X~5Q``ꃠ>K!Bo/lu@P^ꃠ>/::! APA.>A} "xN>&4d@}&#.g 1gE^ꃸ H}&  3g  qp} >ꃠ>Pꃐf>{aOA0Ag"\6CPAH}!fτ,:o/ᩏA}B ZِLPDG}ᩏEjv sP7R-<yP.1.&B5bBT_E}6 WQ>y>>+je* 3/}QN,'C>w&C23yDž2>#We}=lKMτjRwM}&TWgs9*έ*9ʠ-ѼNFeO`TgT.J5z_}?8M)3eцA7)9NWg~:^`'yGT$g(w? SO$,8O {ަSrOo5&Js /֜ofb/GXiE#19Q OeetġoZ%/}:Ĝj7DO j,9bЧUr1}*kšON&@ d}KB\b>f 9"*{e}q땾ԢUc$8>QK:g7}ϾġO4Dߘf/}IM!_.ͬ/}]S#%}Cn,$k}諨                     @>>ꃠ>ꃠ>*"ԇ@}A}A}@ԇ@}PBÒ >,y!/AA}j3SAP[A}A}-!PAPAPAA}Jꃠ>`A} BPAPAPAPAPAPCP^ꃠ>ꃠ>Hꃠ>hcmrA}M,7X ꀠ>Hꃠ>}A}A}A} CPA}A}A}A}A}A}A}r#ۈ宙    8>*F,wr#ۈ{Ch<:ˊa˲{C$k.qk/|z}gWg>Q2Iy}l' }W}ۉB_%XuB_%E/Ӝ}ۉ{aN2AߥxG~l&}2gBbjĠmb>Uh4)V#שdG}hUK1j>io-r`{~$X.vYZmJ^qaʎWq>]_zb.[Mr s\l}xH.;[~^[U|$V%X\w>iFe~'ӹݠ]$)pHs E N֧3fzfS+;N֧uՓ:\}a]ڽMb߹7vNs]bs5*-ս!Y_D]n;UߠaI+dz>]W2SSo,tUxZ53MὫ6tҊyIoIe~gսܮK|):U]S*;NכJas>uU ikAשM(;Lul)TzM);@_UmnꇶTD 'Jd}7l);p}ä/郷ЦtQۮUv8Bn>'jǕ!+|8`I8gk~ڻJ^v8{M]Ctojd2C qJJFW3,Y0}׭nJ)m.}r.6}|/N#;D(CMՔԉd~'E*QMlR8ء#2D*˷}0d"eԃIߪ(G$58FF}dz$Rv}>nq %Md16s`:k YHsi;$},r-gEF}HD}\r?F}~lѧ(ݓ86;ܢHb!s%YnWsaY.qTB}E}a:=} !NPcռלg9˗_oP۷LydVWxA:K=DE[)>#I[>4$l;fpEȤM} }uqQO|'%T='~E})? }KY>9LkW }>_qdk>ߚJgSa?VnF)5ly}GRF+_&};"y}Svߺg@g_EoOދR6^FTךd{nJP͌K ZuMCxN9mTWn^GXOU;z珅bl;[uҫ𞸏p}ֺ0)Z?}>]ӫJ7R^N܃9H:/u~~qj_)^E_!γUrfNR_[zZ篤o=3<ݒ!A.NٮTOCUB_c9&X/͋ZG׭0}雕57q|4vt!ͺ*H}W)}:tzL͵QYK>}KN|wͬ_uzSL}Wh}WAЧVz9z]~Vg#蚯oa){ ]Br_SEm[1蛾|Р{}C #КbWreŨާBbҕ4Y݇_o'ƸU'5rs[wNCF-1vDYSWׅg8k_/o룒NV_WI}un]Rd)uY_FW/3|[~\͉AqwGP~Nry 碞 ޜ+)p`Z{ }]יmܣﰹ7EmKe]Qߗ zj;g[aЧTegI}+{}l,ÿo}UP`%'ԭ 8E+D\z#UxXQBgNb-O,E_bm}ˍ|xCh-߱ z&_D_cUfG} M}95> -Kº_D}jdM}^l_*׺#旯y }k5A}x|rb})>KWa~}k-47C}&|Xaoz=8$ [,wPLZw-J}m6kޗ%L^/|m1`l8 gצ/>53.y,kg~ }&/y?\~EawnҘ$ԧqG σK}M^@}Чm5} hl51>\t<ԯ69̒Mަt BP%¥n z#ĭ8nAPAP-pi)uLėPgF:[v>3]@}\vkһ <>9Zͦ^b y%\_YAHQAiAO,nPZܰYj'ۭOWl/gJVo>Aۯ>D_A}}20B%|x{y7?}b}M}~G4;o{A}{VeBS쮸 f7 }(3#U_^ޞ[ߥg81]2&{y>ʱ=:0>$=n>OuQ}<>9”!}gSr֗W}.OѧrZ|V^uBD^8Czxߓ1}W>㇕>{97 ̽[:R:Ud'Z̥*ƏޫO xzVL9WOաNPlxthkT2?6 }:>>4Wew %*okJCj1w }>>Tq,9]HG5S>.+SPqp:=V{S(;RvQߔ9XtjW2!J# *u/ge;(}Z3-!l2cIh[4J\\ jWhi֔HևW>ry\"Y{Tb|sX4*ͨVLM50Wg"7lZ&PW^o6}DJYC67/b:;MCZsA>՗_4ӧWRrVsQGT,ʎ[U*%}U$/>]7{Gq6ڲ v}U]`}ayҪB\Gq.H\[beґ\]'T#2[8^b۲Ow:.EвK]b~7/]}Qo쩯[2rr2 }lΪ경Ч+(ky{Dxa77EDPևfIR sqGzAN'V}bi稄tQU;u) Xkd}:TїJwyO;S^ Z)S T_w9zgGd (br>>[iĠT07dk&Urdª>9dOᝥW }n}:[A Y\("P} ח.z%d \߇^;doMO}>X}|h]xSOKwĬ"{OZ)-f *}ig=]*H!L0|R}ZU)yF;yU-+lktOGr˅y}OTab~B^~yдﳪ(i0-ƤOH ԷX`|>V^}ѹΥ!כ+d 5x^cWr,RҧJ@}KXװq#P}s d!5K5蛚$ʃg~bG#2JE?>;<ksOK^&<C[nҧVj}*%4Qhd G=jrڛjR{B}(pxX_\u;=o#nK9()}rj}]@G̗r>5Cy yw IDAT"lNiq-+S"p:, %ѦAi,U8]c&Zrh Uii<]%aʕRh0$Zr/_i7if}зߥsW8CvrY߾gJ=F_|:8wmҷý %G}TҧVqOe +oU[5u祕-݈{ RZh{3ik_qKf}CLoV* ` 9􉅘}^+5J_mP'{} AEh Hc/v"Է*\]Է]L@H}Է6{\uYF};o7J_9rwi%^sجѡ|Pk/ hW/ +%oBWҾiׯ#ݤVCwDGP} 0};45Y39N_E};jۉPNZlH|~0ZL}ȢnGeBPk+#M}>Zmv@ Y,awwGuoW. ֫.WR_ *ף'WR_I[&9vN1dzW/3 CȽ'Q /Ǹ=1Wu|SEyi>FA}-!\Ao/!7].Q Ɗ DKSCAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPAPPg^[~){ۧ>y_|woq_W/of`?I~:?{w.ho||_ş?oV?I߅??+?/Ϯ__]~uΰ|w,V~?a꿪owlb_>t韏/<~]oG_~mK3LDsIf~W.ż!oK1-Qܿ])K8;nD}c>:w<=6 ~I9Ri0A0A0A|/C_IENDB` Oh+'0l   ( 4 @LT\dssDavid L. Woodwarddavi Normal.dotoDavid L. Woodwardd2viMicrosoft Word 8.0@@4W@4WDocumentSummaryInformation81TableXvSummaryInformation(|DocumentSummaryInformation8 ՜.+,D՜.+,< hp  SANKYO USA CORP.Aj  Title 6> _PID_GUIDAN{501352C1-50EA-11D4-89D7-00104B2145EC}      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTVYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~~{y籗g߽_G7NUU79 ׄx?7_늫ӟWx]o߸cӟKw,_}ק;+O/wW/|ջO==37U6_}~_>>{^q^ܫ_s˯\?p~~8wl%gwutz?<ѧO_W{Ϋ;nuOɾ o{/q}O (5,YGo}K5%~}H%ҟ~?Nyכ ׆;򃷪O毠*w.:Y<%PS?򟫲I{o:}U|4UŇܷ~BDV>_/~>{J¾ݔz;诼*%5Mީ_ffSqK%/>._]}&syo[59[EU~n?uJ3OW[|WP9췿U)?>¡(~+G_?+QUһӟ;=U|\9߲(G5{~G?#???Ï?#???#???Ï?#????Ï?#?????Ï?#???Ï?Ï?#???Ï?#?#???Ï?#???#???Ï?#????Ï?#?????Ï?#???Ï?Ï?#???Ï?#?#???Ï?#???#???Ï?#????Ï?#?????Ï?#???Ï?Ï?#???Ï?#?#???Ï?#???#???Ï?#????Ï?#?????Ï?#???Ï?Ï?#???Ï?#?#???Ï?#???#???Ï?#????Ï?#?????Ï?#???Ï?Ï?#???Ï?#?#???Ï?#???#???Ï?#????Ï?#?????Ï?#???Ï?Ï?#???Ï?#?#???Ï?#??^/o拻UU7+bTU&jES;x~w8R~ ^m_/s/'\~~S 7/ZGm^ߩYo~~K*Mr[ ~~1>~W7U7+z2.~ ~Sk ɯR-n/ߴ7Q᷸~Y &C~%~㑹s F!~[oB71ׯ yMM\ #夿E~)~E~1~~KJi ,oZ[ 9C~\$LO7~~wMU~~S?6̿boߩ;5}؏w'-˄T-[~N[ ~B- _ԋՋJ֟C'pdw0wP7b9C~Njvr~?1W6r~kw_t]O'e"oV~ejul?n|~KD{|ϓ~S]f%Ryj~ϟWXyN# ._/:XܑK!U=@eI!ʆJG/hV+Lfқ \QWt~_z5b`WRq|5F/16Җ di3,`Ԡf-]-Vpo9J-@?iRS7?#|_&MWזQgkv}~9_m ;vdnG + g_zZ}~~lXmj ~vT +% uà_1V҂^a%tYO[LŪ\ã& şԆp`N< C PgRкӁD<:*1?y5umhASV)||V[(Fߨ<_im%?zef_f=lyE~A[LF7s$Z=/Q=@~^OT c#~*?_x.sTٛS/{7~RU:H%7?yQ8e?_4oivO9l<~Z&a%~/OV?' &mxW,KLg/sUyvl>wM<_o \Kecf?Q-kc7vrh޼]E7~w_6o KWK?0֣ ~bK'+_?!q?_=5;~PoQ?_}_ƯH<WmԋW<_}~x i~8 ~}^loo_;opwhsE~!~"U-s['7O7{ Iߚ`~9~U|*)*2~.cN~?ҟ3t/Ov~_y~Oo_([~B-w*ꩻ~L???ۭ_%ȫi@Fk`>8{~mTnJo:+\܋S~Hqv~vLۋJaA~s(`sS|ï*DZ\ ~fͤiuΔ__Uʷ$W qZT M+_bL~1bBxS26~] (d3:/ns9Vm (~aW%8`zDTcOuM/\_2IZŞɕJxB8W*N$)NIU8mASZZpsEXZ-W/J1jXxUϩ:NzywQ;0~ܭ~vT♿?_x(#Hq^,:OM~ $~_p_unFoo+gwi4]>`A_I*k#CA:Wt-@{ԯWvc20w*UF2Ѕw6>VsKe ܊o-?N<8~~m͡[gTNH\ t///P=]MHn~yf~ $Nnu<cI{_* lc`U;'U Bc`%?)Jq&[/߯mA!$Ew: m!|(z^hFضuZ^Қ5߆~m :F[Z+=U=<_َ~njgYcT띿QݟfBlKc_)Y>nAšwEv؜/8 s 4lo86pWpF\ƗMߦ~m{5[TmƮ +}l짖H!,>+*̦c[vFĦcc|Ide_~ ˿ !aTj;ot~W;EWV7k m3/m[΅'~hwZ.p{TIaY_|#v,<؃_[׶U1TyriYy~5Fa[xuހuހuz N;#kt'~iW$u~ᗵ.-@RZkwM8?BXM;=yCNu @UCw~9ne/~jbac'~)˦.w{@n~?~ ?}. o^Ra~2Kf߽Uv^ؙ}wZzُ_acwG~~K[෨oY~~ґG?????o`~~gOÏ??6 Ɵb?_Ï~~R~.~???Iȿ~~~??q/~G-hG?/~i~ԿԿH-??/??G#~~~~~~~~~~~~~=oIK"o~B͏Tؙ'nj2/ond_Hj?%şpz+߂>R'_ag O=`77F.F.d%} d~LxC{_ӉV߬#l1ͪ>hfT2X/bvt~ ~3"J̾~VWoy;~iKKzi_hC ͟%+Th~+R0O ^a2obf-ʶț/گ-ܶ!uyAi*QȒ/vUm]}aJˆ6;e~{د[ UlK%_Y,@Kz] ت1m.&S*Mʋr~nAGM>tiUdSrHM[5 __*5U[7dԂQ"WšM~7-iS pK G氩ЯYnf/mDv*mZ_zTk: ێn*E{ VS,CAv+=v~3Iׂp-ܡLV6OYK}Қ d̸--4UU҂OY:Z.~~?{G?o7??~?K?z~=?6,ok??l`J+ߔ+~m?ߖ~1~=/G{3~?)~/S~-ȿWԏǏ~~Ư,fe?#~~7_~?ֿ?c%~Gcee#R?_~wg?#oӟ?_|Q\q~.[)Do,2"PE\ .[ G\K3$QR~ϫ.{~s-Fir1~~#OV~FI tbU}5+)ei _<G4y_:; @1~jr촲Ưn#Ҋ컑_jțۑY}7˅ w.i)b+`-P꣰O߸+%V~!TĆrmHXKS]ߜ,>6V lk\y`~fKXz/LaV=o~eLj=oW V2Sm78=~. 5wC.-;om+6IҖӍngn偋ߌ!\ԯIfI~**:Ec[]zÚӭPl*6n kО~Wsl>f]7n#MǶ~-*or//g~yS]~.pyn߂Q{B,+;e.߹2UC:rȦci;݁߹e~]y'O-+6&&PӶIu{v¥7k!sF ~e&^e>J늿PsZ{BH;݇_oBl[y~Uu=,,vwεw !ֵvמtUۅ_90/9ߏy(o^ Еc!~3[M.?9!l~W/8݇_E}/ov"~W)y7|Nߒ oQ`nR;[/+lƯ#~R;;>v r;įp??,k~oFdᷥ~~G?&G~?H~P~_G?~~~{c?????׏S??d~S({0V?s#K7P7^~/~mK4_v-27|4 ~sAS 76U!|FfI}oӵbv>d/#~s9~ |/ϸj1\%WZ뗝&3߅`^bO=_i^N_bx{n^NSeisSy=2~ff=~㆖7ͼ.Oe_rpf_9W -?SxCo(4N3귆2ThN<_~M]/خIP[M_~W?X%N7ϭU/[W>r|?٦Bj0+_`72~&'ʞ[>lX+OU*m:hC\JdCO"R;g,Sfl*mFHR*'`FN%iΙrUt_6> m5iд+mE4Q /''O q~ eg_Jy61RЊYǯe,s?yJ^P䗊i~Ua7R VH2 / )Iv\@u!˛|Q~R:YFBϸi ݯv^[вU 5jj|LG{??BfN?ЯeF?h|TF<|FSgɜd~S~5k^a|lVߤ*˓T~Q_{ü᩼~?YJD/ܻjG^į2tuF2Sޅy~AQ__/UGp9 _/QG=pɑ!~.jS 8ع߹$O^0+Y^A',8<' S{?<Н_|JsFJD`=U/Kc~"{IXܯN{\*q<0Mڿ{7_/sBY}|'V] Iwt~ Galf;KGoKFB6[iǤ1-ݿ9s<23ߛR'52w~k`p'hOvC@u/4|)Q fQtpHtt)e˿ѯ[z~o`iin1~?ٯ<%l3ǯFr?L<$jg~Ɉ)]|.އ*oE7ݮ_>篙^NmIX?7^k?><Oˏ,oW"?5-/ ?y_ ^U%So_u~c_= 1Y3tg7Cu~_Mh`-~%aίk`OO y!z(?1xP)~ lS]ҶK R~"W~Zz ק ,K߉G2$|%xw}9^re7Qy{k8d4+ œorKq?m34[e&J[^c_8R|[7֮vߢE~3l+{Z/<+R%"_d~rzޜ%z>_&|/o_e_~ka_`?o 0X$~b}#^?gjYï">g=Q [ L>g:>~ҟ@{<;_p\t_flK^t׿;_4q *~~#POve״DEM]s*yKW \-3uV'L/痙=X?S>ߢ[rhoƕ.14y ~=&/~)?s-oq/Im)q_Wgk'/7ci{pNnTX?g_.σh]+y/h|ƒeZ L]''?D7Ho gGal}FiSlo^4E]'S~bV|%+/?u~~8\_0Z~,Wu7-du=kR]h}Uϯ&3gKu;Ee#6!'6=[363cl-`_j sBtLjɰuE|wW~PqN9;lb6,;*f5],,WcoAR7}{Mu\O˺Ӫ$ا ?ncʯ~Qi}~]CPչVTcݔGS5~ydԯ|Nɍ־_8/Weԁy4gT K29x0XnJ_~d5~޵_j:~}/;wN~y)R'&>zuӬNr~Q6֯-M8_v_p}~S?d*'eJvZ?mƤ21NѮW3[VN6=-S7Wv~A߯63L_VS1րN,eLʯ"3$Cqp/kfFs0F*ZtMW9ͺf'˿d6ճ_ߵ_x6~<V?b4t~娟Uov^:ր/q?Kow_rbWU%~W~arHگ輍S /'DvOWiD<_)=WnHF:i~&{Rr_6/w}; !&?Ec,N|_>Lsed_Un:/O(nN'z}Z)Z'ky:b_=m;NnMǸ_UK&ϋ9=vQ~^fx{?ݯtkW>b3CU'D0S {u7X LWrspR1KpB Y_pU?7{p,+fP ~]2l/)~r.jjfA`1fk bߩߤ-5KQP6g:ax~]7tWKP5ى_=6<j꬈XeWMU]Gd;eo}"wiOGj;f]pJN []9g_xcWE-9W_Ώ! u3:ŹGKsJ#?9*=b3ÿƯ9Hc/-j[]/`s9R,kJ1:a}v9n/P_i`s~fLѱ5jꀥw/&kDF:u[|^N5Cإ/,j)]~*.ίN$B&POS5gtkn:WW~y+6 K>?ot]NQ~eoʱ::~~)硺 Fa @_̷/ź M}Gp>w<~o`˒g_ !#]|vG%MWOU}Ouuf¶zo \#JvOv8W upZWI?\rJ&#~uŽ7shp*KOX*Xޒu4N:?V:o װ iY}|B3cj-Uy=Lv tO_l_#w7 *?+i 0X8bei&jjm͕bfwx*Bnw% !.m~N*t~\Mݡ;2?RCMhbo@[wF0~bֳ\uGYꗩc-Z 'ߢU+W#SW-U?s]A˅psK/KW|:p_e_zyLş|ǚ-*2uiV}a0;[A?9fe ^] h QgXIV|/N=VIjT~gsV>d1|ش^ʮs fz^!=_\#z*i[k^}FsэX7-ABf [jEzfᡐ8t769$lۿnjS: BJ ef罽?1ګHc_jzgjW"rmQHՇf L\h~Rٓ~'M[o/n6Ll+}eqlү^h_M_+ʃWoN*աk 4'u'Ba9Y,hIwd/֗o˚wl`BuC\j gʄxH!,8bY²; aAb+շ&\eǚ)N~yoǪ1??U6˪*l 6% ˵Ž%~Hw=Pvg__zu Go-wrJSUer BkVfpL&_tbӛ}R_Wx]t@ݜE~۷ZZ@fę)7.pK ~+s58@tdlܯԍ!i~mdZ,Ͼ M֥{LݏGp,ʾ W-gS_W D,Y9Oܓڱȩ~j j>n@\S_@?uIo~B;O5#Qt~_K&y#~r5.bɩ?+\%0Wx-I:R||4[^KiOt_>zpAj~}_VpmZ3SyL׹׎; x?Ӑ?4i/hjP.ηzN@_]=O"ʖtjީ}v'?JiȊT8Xu̯i@|a yMnK[? /\FN5Kڀ^IeKbUm;9EM%X~u\a}ޯI^S\d=S_/&4-O` iTm٩'k6&/Q{&Wπ+Ku.ݵ[vrux>-{bW7LGMϗ2ʼn&ViյA@@k;Hē#ir)\*&dܯxg+,Ϝ׿xQ;O:5uɒ7Uӓ&+P\et֜D(dKXeXο8V_WYW_(x_5pvYq~Zcw/JB(ONZ\A22 -ڰ˗}g5ʔ((@|Rdi L:GT71TFSHv S3Z9ءW5~ar7FmN~G9_|\Ev8}闌cO[d)~T#Zϙ9%/ nh\o /]`)~Ͻxْe/ᗷ~OK2x++/5F~ŋZr.#*z=Я|A'd:K~]8| W|c"l=e珟!?^5<_0WD尟%kL.Oi~~~':SR%[[|ܯzkװ7VJs_Zu΄GU6LKEݴ~;E=x:7 dKoꁡO _~A*)7LuQs_/_u֯KP`-X S>k~;ofӽk 䪝R;lzz`l6k/t>#D nU3[u~B ϛU_moϩzՅzSiÑ9B~Uuk?KHBկEVuzo_<׬f{y(;77sU<47&F'g&[~⟞_oFKGzz/4~*; c8Ǚev E/6zU>_(eO,)뭛3W={9\k'_̙pky?>/E iލʟimh<_|3g䕟j'/=_IK _;#f̥_yU.~"ݓ]a^?d~Jgc*sS_cc Om}?(Wu;ϵYl˟/4%~aիp u'zBn8ljz?L9~i~l/%=tB]?Iƭ6ʩgJ ?t/fK[\ sǤlܪ'@κkrYc_ϻSNW~ʑ'=UU'0,r|Ske:r.œ2WyԁsYО"z圜Ou_Gq|IWv鬷.V~9]W4 U=nME9]>Q͏}ϋk|CO>Og";6\{QP~`~^ 󈣛z¯T'O%@m q3TX*=;p~fo5\'2U]w闵TEi`8XwBh֯?.HlfH7nAz/\n]?=Ŧ~]߰_Q+鯩OEFYs4y؏LkyW\??/zjCrjxbOW_(f~ F5~~(]WNe<ޜ GXg̑(01~#~qxsgg9E?sؼ{gi~*-}|Lw: w`7v2L~TD?~~.~faf_yT?̨_yv?߰R;bkܯhܹ~lR+j{NqTR Ս-4[3>evU´d/Q,U3.hͿ>ko`_b3PEiANf_" '~759@~uǝ'y/U7~:_X WW<: ~Dꤲ\?Vc{g@뎑jr_ޜ O T *_y@6;IU@O]u__jM'3]W)/ ~N2~w_͙֯]+;)ޅ2J~'f MR!bz~M5SK;~hWNʯu]x3ˬT|&~f&gZR0+Id }()~3_ߑ_5vKT%/G~˛,?ߜuQo_x'%N*J3pl헪>@p.^mGm/Օ]B/H~bg_U ¶ߪ]y=ryZd<.W~|?ɖjGkR_֯<#f?w=]kd$Sٯu!>چCW-֏GghLܥK-[x]s~w?Pk+_E4ۯs߹?jZ?'?=C-lRϻϹ+qCK_i_sWp:?]; ;K𲑢yp~-K.Jw>?"sÿAЀ/=hUJVuԎBW^]0Ho:-eM.vB L̚Cw_77~K2g•e޳ވY J 1E˝:r//Nd'*BgɹX뗈Lx~tȅ~Gn/4WJ_i_,( 'Hlh[3Nhn>;I=ӣsR(-,GOuiDPzίvοX)fnֽX]+oQ,l~/8x~S&5ΘWzն/y_t7uvW/= ~#0Xϩ m/wL_^W鏱O@V /k ~-5~u?@,|Co,vV fMS~(-"rE?r\ l/V8k?~_*?a_x \]YVnx}g(*&3 b?w{c J~[_cRD \ *,q5X?wӀW9jMʯ|^JQu2ٹc_&?k[ԳJ߷/4JWn- AE3\yUa_a7^qvKwO^7yJ;LL۟%ƚ$WUwЇ+/u>j,IP~:Z?W‘ϻxZ%Džg7W\&t%myלe7#~R<\'}?[_)=_uC$T^p/r'NZ]K!`9\.:֩:zr+kL(nwK"=餄^W oh]'ӳ_Rӏ&wC&ڑ~1~ [ %~.~w7~~w7`Zc8fTwU ]^\3\WltI1%tk9Gm}u_~3~l'~3 c7Y'ٯy\ޚ1_3~w\- [ b>'~o~wH?6[9~mfߦ~~GGÏ~E dM["?֏}N闄-c̐,V& Y7/4Q7!}9G 99}j~ ?_7Goy:_=x\7']&=\[} wTVJ&O)zCNK4@dSCſ;sy{5[3vWFK@Vys*fbKoG>^=+ۑx2"hǞ굹*ϗC75v"ڱfn{U^>49Uy|R&e5X.uINwg~i//Mw7SWC ɹ˸-+wՀރ-sl\1-|xFwdu H]ۤĠN0;Dj(VK.wՀى_55sڄ\}~;ezCnUiU~]Fϻo3w;ۯG L;tMlBVucW/O䚑*p*6ON +4f0b`IM:\;?GBMwP/ҟ7~Uf xǭ<_z6g C"+C?9I0EsO~_** M|Eү6~b_a_9/o<ѯOW7˯vES֢:~nWPTΜ_m؉+NO~/ZNx9\ݯ^>YLo7+v<_<_pnd\eu~Zth^~ܑh\U՝~AѮO~Sݓ{kiMs ״NIoD;O[2ͯT7\ ~Uoc4(>'>_UX6z~WcoJ𫦞C=}7_SUor~/ѭ~~=?:;Sn?,Ъ|_ծF|t~_p/v)*Yw^ߕw_~kb<|0w#~ѵ_5YBdעΛ}~;xX'=~z~%f|zgrLo_ wWoO׍&~uաߋf ~>~B_+k.X 8k~3w)WbKEüS"A9o\u7O^n/oaK?߽HwG]2O1?9=8Jsnop???Ï?#?????Ï?#???Ï?Ï?#???Ï?#?#???Ï?#????Ï?#???????Ï?#?????Ï?#???Ï?Ï?#???Ï?#?#???Ï?#????Ï?#???????Ï?#?????Ï?#???Ï?Ï?#???Ï?#?#???Ï?#????Ï?#???????Ï?#?????Ï?#???Ï?Ï?#???Ï?#?#???Ï?#????Ï?#???????Ï?#?????Ï?#???Ï?Ï?#???Ï?#?#???,{U9x?._uGWէ?9ꏟv?_yL>+;w)~L_{#x;+ӽpNog{{ş{~coO>?+_wӾ3x;G|}Du߯ί]y#?#)+_ʷo:ۯ>R{ğV=q{g{o8~d~.>47aaM}?~ciouʯV5ߪ:ӟ^};oӟ_C{j! s⟋o;?9:m;}_gYZ埶#j#6ǏG[_"Gy(_}mX#?xl 2zn'~b0ൿD *q`ݟ_sUV?4~xyM~>O?W}❏F>O3'O};TIط_UoWŻw&i;wZa]߬l*zd;d>?޺?K7>=:G#ǯ*&u]48Ƣ~UOCo_Bpojq7UjE~MqRf?*S/A?Dxȯo<2WVt~.?4~a(o_yB&R!Q?龉V!~w/oQ/oo_)4/~AM4?g/ //ɿoJ߆W ԿM;5~߷QNcE~p[ E~~ ~bOE~!~z~zP~2rh$?엞r.~Sf[,9hϩw`WRͮB'F.o_pW˿{$,8oB*گ֙RM?~7ݍO|p~s/3Vy/^u߬X ;\/8J+ω~ߜ҅Eg?;b)x5,)3d01Z^iH*|Ɍ\z~vk9*Ö[,Њ)*;:?UVgi~;eJ0:_6'2w_p^e`UL˕w~2)mvnφ d-pӶ$S)7XίlKb_|Cz`?Y/QXM9?,mjCse2}ZNNHQfsg"O% !mXMgcJuW VX;<_ %@O dPkp_ҲU + eԾ!ɫ/'_~DiKFRW,ˇ/KϵFl̃ڡY5.ly_6WWz^i]yAobt0dx=~>6oTtgmkEf?whys0?}FxN*gߦRw}1)O,Yg_ȼMΜ{(frL#~j̹Mv !l\mV5?PnRi*~|O#~Y7t6rOuؒڵla_ȴ~'],]G򫗾;W_~,C]/uOOYaW p0:Fmj.k׈5ϼ~Rݹҟ !b]c٫&^j͸F\ _@rςƯލ;F͗T, W\Q"0sUWMrzi>g$j:'sT .jh$Qݰ6EZ4 ԯ~R~zcOaӑEi3SSg ~ZGu4 5v]@sͶwi:_GG'$^']se5oӗ/NvA7˹_wi2~r&?Y &tc~Y7xh߯^<ޫT%?бz rpYVPo# O|VOeì/-KU秦̇~uC_9?F^qZR,mylTtѬװ ]V-G%g<\YjܒQg$PR>j|ҮO3T> dB}.(C<>~?f 돀WJ~;w&L-_9=g!?~?I%k7`qkO'د Pawa~b1qk oyI7kC-?2 ?_p?/J?Vݫrw?/,7w_ٯkǶ _Ww#_ywflڮHcO a)Z8Iۯ ~()|~~ݽ#UuSYn{%w_kg>u,ߑ~5Kx`~ݱ[+o(+?]mS)eշ[/կɯ& ~ZmKOoz'Ӆޯ{kI*V״7?Z)YZs{ۃI~P/Z~x~Wv~":nᷪSi -_Zy!~?~[Wo_?~uq{෥~~aC*m+W<~}mQ/G o~>ߦw,S~;Qr39߶ߦ{F!?8'%M;`.!~4a`mc' ~A VmW0w3@=asGP~A~0Iѷ`ŏoXmd}MRtWZelVV?<~[ȳ.~Y?N@lϟ@fCg__~Cf.h4V1P=*i?_7t#i VǷP|Mt/_r!7:HsMP惗d]: #?~w/,O>ҏe#[^(8ϘQ\h= W>קּbg5B{oK{5lOSCcy=Wׯ=OdC3$sx~䛖q|BēX:!.'M ƿ`M@i?^ry_M"rňxZ-s&bIWNzlbOz} *?ɏV@}J([9|rڃvNr6Ai"^~ttZgщN% T}ߴi_>*?Zx_Z}.;*?{+/''`3iBFk>8NymT@>dڇ,zGq߉y~ǬgQ\ ޣ_2viW*#IJfƯ7twRSkH@o迷,_mMǐ9~OuI]x+1~*`N)~eߘ[ǵ_~fxC*~?w~?񣯨83~R'7L?g7@cڿWU n7&OT~ӥ$櫫c%Н_CBF:}_ zbf){udZ/ę$sZn~@%~Vo;u="@t;uOڒgMI+p_=D߃ٻov߅/k0qS K^m[bF&s *ỵ҅~\7n(~bL!?z_Я9)8}zB2]sOaكʥ~lȡf ?ȯZᗻ:CD?9׊8oҁT3mQ,L$N~r?81Ƒ#D'g>,cK>y~+ l$\{^2\?,gqYRu 58ׯ@DLǹ~* ,d?1zRE'ǝpM}2B#}Khޮgj۸&\1}{ ~ 1s\~7O-p{T~fURG/ߠIɃ+is}[qɡۗȢ ul~o蚿 I%~$]wr:5&pȸrC"^ONm@xt%pϒB(۰7Qo] !i?Vqoq t]{ ?B vSxJ]*~*"}\\;(?_BHtI⿸ ~4~a)(qc:~"*~2*~muXexuk5M~ 6uo~?tC?~?~7_X~??~'! _~?a?~~/~?~wdI~~OI~~?cC! ?ψ_?E ?S(? ? ~PP?~?~?~?~?~?~?n~~[JCpK ෾HB /_ŏd1՝_ Et~e~gix Ze}D^Ïk?uq6뚿5&9>Uex ?䢌/CJ"^c_cr?+1p?A\U~S>>ߪc ᷢЏm FKa] ~ ~+ Z=|fu`9Aor4z,|?6sut#16ޞQ0~ժu իN?:6 cbkCO7f-u߰Y?4":ۏ#Z|,W;<&>ٯ i"K!7&_8dI"&O+p";4_d\~ܳY?YՁ&]m@U\ s4T-Xc]/Hb&ȩ~}LG5 wT7}v˘"3_jSHϘ"36#DkiDi~7u'.ע,Drй f_OrL%"~ g3m?o=e:,@N{>Ag٬j:K}e4"~<[äp4Hg֩5:rfY~! `,9Գ)BDgYB*[3?gQ0I~}F,I'EaG?GQ y<#s 1g}FSGL?-k8~/o’~'~?Y +_H+~??<ߙ~~;ȯ߭gaq@'w__S;>?~7 /?~DR~/C?Y~ ~a3?!p_~[30~;~_I~ ~kIe"7/oSo ?oޯ>,~S y}o3 [Wii/$J҂&9_~58~[џO~]|Ƀ)Ngk/lOֹ6.4)<&$?x6ͰCD'}76u,44$.mc 9:}qtgكZF}gO!pܲ/Ik4l$Y~oMX돋HlCTɃqk-),U|aQKgugY\~lxf/mm3K'y|ObN9~s;onRWXr'}ʃ~+RRWU1yP/4_PR}@3;3#f`<~ s1us% @8-R1 ~_ɨؤ4_LɃ䤭3^\~!p3FG0fOHd~cOh8UwXE79r(~cU~c"t'ȚI8}Id~C_#J1;߰9ߪH ~`UdF6v F&~-zd+wz *[|qB]|Q-~S_| !@.ןtU]¯_,#||W͜_o:*.LuP=Eӳ$~ݢ?v־c{ [݁(kƯߺB_oKoSXoC !2~<2~ue(cQF/1~/'>.WoCqv_~?E~ ~[Qw~~ .~Co?= ?~?~+a~?~?~?~FΓa)֗}1ƿ ~xHŒ s47.s3|ѳ} 6/I[9,և[WF~kBu[>VU3?wUE0o_2D1[Qk2=P?=/ߚ"/9W'N~re~χ(fnAϏ*q;ƽ ~uҽlWT/s[W1熖_a܋n^mXD]@spD>,{Cs:~8hr*Ӊ$owiI"Jk7s~uw_lǒvՁ VU__3t_;[5W7?,z|es\=r_4_I\Ű~WUkn`TfL~frS\eHF+ ϩ$9s}?Oo)˹kV?&?h+77iP>5?6dNQ]T)!藙ڼ~]Omʱ2܊"W4r>b_^O M ?N'.RϪR7R;tWDb~5(Ig^7T$H퍜itU+u*vըMhu3~|?խr#^ ȸ_@? N? X^=#.Cc_%S5TWqfZ3j*SUvuÛ:Lz3j?/9Ngt+Qѯ3{?׺X>yFʗtfd}~b7G1?̩.k%*/Gg{~Opqq%g?瘕u׭#>﯏# a?3xxZQf2;yzEs~|EY^ܯA3v_Kg^Kf]D4`hK Yqgw6h86O'̪w1φG Xf=Yc!e/WvNb_~Ց~#d jO \l~Kt~?5iEO"mfnu=W!i_o>;_3jrZ4ǏغRwy~/_]l03b~lb"qu`uÎI_ۺuK3 ;,2?u&ۏ3d^,~ˏ7zvX'uW8Əo^7?ZYgxJJg|EӍq;S<<=OMm=iYZ*-a`UUJOv(_V~}kdž7zdh?NfˇuQq U'_s?vd1î!E.~O7r9csC ޯ>Eq/a;meB~:(_~o|Zɰɯ6 }^Յ_4ApwE͸zEU)3EӣJ?;рGg~G\旯sٵon{zfWk8q;,# 񳆡X< ~qMŖ-Я9ί!v5[פ۔Xɯ?ޯѯ~]~i~A?ˢOU*N2_7*~,9ǖ~'.[~~6qs\_xsDl~`~X8hF^v %^$=gݿmKᷡ=s mu|`~~|pE~\ܾ=zk~ou*naȕhoS ^u;j_`?ϟW<2V~ %%\#6أϿ9W:/ݚqFJOZ2gp?:~#?箽6?j_9muLtݼke+k/5S;,? ?{ _GV  Aퟭ" =( [~y@WG~,d6] x=ڷ!HI_{K?_rm~]bj_<ٯ{~_`u _϶WV'>Oq1xb'01~GSk_U9&)].[}/l>D?Ɔ$KmnW/~ڑ!I*ƛ.!g4EU[{8GV '?x^y֯ KտD!i>hO;r9?k󬊎6+5'g:;Sq7?7A^`7rZU }4j%m_lfP-i_sOuWǥM|9YV6'76N};]o[K;Y_>_WLn8RzҤe/}<e,kM[WMn҄~f-V5~"̯oӯh%}.ӯFd[N?7NxF~zOKxsWLa'3V|4OO~ïpˏNR9LhO£S7_3u fbl:+W~j4?'yJ_~W?c/YP_'b3GUz(YvU)2z MJ%įKHwԌ\ү B$1'l`~{I"kBR= 1*߰ ﺗ))+/ݖ?ĬYUkVkԙ O_/h ?o~V|>y]yxeajWPYJ"~]nG sVs= ?վ+YtEݾސLOWf;.8id쾙}:g߫u7|_s:œ!dz߮Nq^ѯkt|OjDWΏ`:8o{N~hA>?>YT8=w.G$:?՚%~r܉_aο :8B?<-1SWMD<~]F|L,zx%R0u0huY,㧎nMj\ᗺ_ԑ~E|~w5'fT<Ԝ>4{v?_:eU=tdLձ@_,ϯaA3_I ҝغ嫗 㦱c}DN3]G15ԳUmlwRϷulKKJkb%5vUe\Cb6VVYK +B$7b dNkVRGmBp%u&INpp`mj`t~+Jz,e&+Fbq><3U, S?6Nlf**?}oBm\C_V~BoO-/3=6^_@W7k:|T}30|>`bˇ^x~#zV@?_3+z6HYˬ^6`v 4>ujWp<p~qt->?͞~:?H~G$v>¯qөx2~q;v 4_93܃& IKKnGnɗa=~m~]?-g%Gk?],`~7'/ lU3oqBE~c& 15͒0]~G7{ zs~1_=ع}az֟ή֖ck`^p7D0tdT~yk}2В h懢uY@Y.1 &_u Hƶnj3:'$1;xT~T;D9U4љIBdגiwT.[vm*"J~V^I߿S?nR_d|MDu cy으2]~uPc(5䈟콫*6#]fi,ӚK[ܓ\ ;)~ti[$-rb^PM4JWzZ5ӦCk!t'uE,;69j_vm?#Dq~~mnɛ$~/?x[!4~+s-i9[ͷd~-d5 FtM?~v?HM?UK ;}*.A`d ?~ ?_nq4M lK2ǂ__mVKد0~~f}XmIs!o7 i~| 2;O"H];7MgWxx+3E_?ί TAfScc{? 7.Ggj ¡wȪ>"UǙeXѳm'_CojJp}xק|L;/YS;6 8>냭@OrݴeO_׮amL_1Cz]V?}/~ˎ4+\}r%!~TI|d5Z*'^9]IT\=U-ΤTz=8-_߯>3'f{'jLaHƊ~vמ^)awX@'&LDHt$Dg6bu|+IDZ.Rʯk+~{R):1ɨz4x:|ouo;W ~E B ১D_-nxѯ#?}뎟M>%5Qoykho ><,-~řgs Km9ձޟA?۶C}6wM;L9WNO?ߓyɃ#ޏWތ\{w?WOC9Y+ďdI_O$uc7֡o~c\']~_m ?'{rp?{io#?W+'WL?ohOO̯N۹b7YB`U~?'k~Я? ]؜_]t?4~3~cެϐw 7+fꪙ#4ď\_y\հ^?vvg9o/c~2؏:^ZN6Rӯ37gx;L '3G?l _qsga{+WOn= b_*lc?WtU4U꾶я[9=W#kIUCX|=LsW?k~[l%Y˽C>.Llz1|`QK=x~\US_)oXpᗶzƧ1+åZ5Y~Mc{_uoիVo~7IkGZDGڿ_:׶okgF l֯4 ]WE7E6?{~մO2M_jc 4/dEg}?Sڏl7^rfOގFa|_~_jo~㼒o -p]?_nzH&~(^-֞}c)[W,Xۘg-WLяnOo ~?O/i2G?'-~8<҆x>¯i_UTػxȟ!֟mDJ7/?Lܤ?xb2jN~56?V:>6b?2ϼ7bg`]n旘zV;J7?[h1o؀?˧~zx;ϭh1'Wا_N:;N~ï'/?}>um~,1WLįrP׍OXr{!oz&9@qZ+{'i80itZNYwLZ#8}*DԎ"_vX'EiOLڹBŒ~}T \ $jB sz:tz߯/I˚MQG>(FNZ-T-Glú[;uC>C_}g?ԯqqy_aznڹ4I?a&ϯ(yzW?PyW?טGg*xٹOpM>i8Uq Ӟ~*7<~BŴx;̐rwnA:S.L?^Qrߡ믆緜v'\TJ&=ʞ٤yGA<'F[~ԈE~?WoeU+~ ~n}~ _?Ki)kgI<~WO?]?q'cᷩ  ?_Lu~ɱ~y~0EQos+8鿃\+#QUow$`_LO^?;?Or@8s%N#Q G&ܯy3D񲼭׏ w.kܯV~Z\Ҩ~z?iOkVJmqtĜAa^3W>$9Psc_|ǯ@jq߃V#:?oX#:Pܔ|gXu<9 ~x149L幚?g7#ծBwBOS`_aZP]u~zkЇ {+MV%.u<0}t~W`_ϯ:|4~kG-~~k *?巼2}~Ɋ.\?:+^ )f{!X~Sn~e\~WTx~xLwGɚ6\ҺFg.'dCȚ:|Jo ~KS[2wdʙ~M;~512U}ٯ)[ÓEi[YA~Gk7QWx[W)l+cn?GY~k/?rX%lϱ@W[r'l_ t:=xl~7H ~WE's_"~O}evܹ͌~ua8o_OI)'JZ:܏3# M8K1̸+p?n_9:ZϫjuU~:-"[4OD4|.iVuUǢh׏+o$-~$C}\?H[ZWww~HN/?sa$ԏQ ◚,r&G/_ӽ63e~$ďm?z}nZMWXq7c^_G/.͕}BDW0;S5Q~ ~o|xϿI}qj"Gw2E秏cfcӯYDjf>oYB{f#nt]4Z?=&ki~UR_ïƯoѵ~~r7ԏG꧷]s|q-~">:W.ҵ?c_;ֿZ_ř#|+U-~ɷ_YZjW~M~H??ݬf~$N?W)-?՛{>:Yx~X8q+?uWt{9d_v?U?|N&f_mfq.~q4Z1=kIM9j'mu}u~"X%I$уew1ɘ:T%s_b3~DdWNLKRӄs/H_WO_/8z)啎PU51Q[os צ?~/1C^z?\lSMi_=5^hg㹫_CSdfƯnvX[G[_m~O_/){W.]~{1׮vnնՏW}>@[V~o>G%m_aδ;܋>Z1.~{ Z?5EOϟV[f5}Mo71~j>̘{c4ڿꔫS~3//vE͎~Y~Rذlw8k?_˿&˯Iد lk72ޠ9f;Y*׺f^![qN tׯ|{L7.nnxwyͺ nFrԚƯW"9NWT~D _挨Wٿ_wVi 7Io_t%sO_:*Շ^qN?nU:,ӏwO~⃟ ++__Hk>R} ᗴ۷?ۚ$5hR Wj9H2_^9NKЊO?7?.^_ӯ}AvZژʏWzmv{ŬS'F2ζᶡcW1Ȫ'RΊNtOdTrxPEI?;l-f$kO[ٳ ["Q;nG1ҝ9i/ qoqת1+WU~_*~8.-V;]Lf.]ۜ+g߂1 ~+_(6[1Q~ҳN~n?rvr0O8_~_M~%6UP(6NuFא~R~{_ ?oCߩ~9wZߩ~?C0~~߉A~7M~X?uj?Vo,Wslݍo_Zn_@K>iyߚGa`o]㗛3x)VYw~Dguuߚ>vIf-~'5u_'r@oS8^7Pc>(qi_9}z/W|~LW+p)foGH\3o^\/Xo_Ct_u=䬂U+!?E_CwQQW8ӯLJr+>>?WI<7|| _U}B?ռqsӖ^k8w _tc*ә7">WuU^S_O+M"ܩZ_'~6ܜ_Ot`uԅNb~|W^^k ?5檷f.y?=wIf?9{_^s ~n7=T]1r9^fQ:rya<ߧIW SUNK0Tf>I2Y_jun~ʈgC-J(?Jӏ ~3>ҒLsr:~zbc;V[3KRj~5i 99ᒕJKP?Wf?Af2AWZ=7~Cqv]rHuExt˚{4կz_k~o|(ʏ [T?S@? 9Яݯ*.Bj͏?؏nG!?C^be?9Ո=g{.Gӗ_Oj>Cu'T51I}ԏ5Ͻ_@*j:GnAҖIBW[䧿%?e•E~;m ~~ITzg, aJ_/[M~dct^nD;¼q2Og%O>.bZMl Wc" ^>37QSoЯi?I~{,1_ _4]WVKw/O{w~4(M߸~~f"?9)3~~U~S2Y'JElX:{X}GOjF%`^S=~?'2 GGFl:lKFB_1Z?u^q?/W>3ZKsSϏ'}7P9y/}~oo~iU#j{sɂ~z~Zf&~k_JNR+B^-yX:y!?g~%v-kr*fZo_uŬ9 ~Krm( 6E[•^Vt5G~aH_E%b7ghT"zv^3 *@VV 4 Heading 8"$$ L)*$@&a$5@8 8 4 Heading 9 $@&5DA D Default Paragraph FontRi@R  Table Normal4 l4a (k (No List R0@R 4 List Bullet"$ & Fe^e`a$m$8B 8 #4 Body Text$a$h4@4 4Header  9r H @"H 4Footer 9r $dNCJbR2b 4Body Text Indent 2$^a$CJ^JaJmH sH pSBp 4Body Text Indent 3$0^`0a$5CJ\^JaJmH sH LRL 4 Paragraph 1$a$CJOJQJmH sH 0X a0 4Emphasis6^JHrH 4 Balloon TextCJOJQJ^JaJjCj 4Body Text Indent$^`a$>*CJ^JaJmH sH pP@p 4 Body Text 2&`-DM ^``m$fHmH q sH 4o4 4 emp_italic6^JZ.Z 4 TOA Heading$ $*$1$a$CJOJQJmH sH XoX 4Default1$7$8$H$!B*CJ_HaJmH phsH tH LOL 4 table:text xxOJ QJ aJmH sH 22 4CM13 B*phJJ 4 table:ref  & FCJOJ QJ mH sH LQL 4 Body Text 3 n5CJOJQJ\X/X 4Heading 1 Char#5CJOJQJ^J_HmH sH tH 2)`!2 4 Page Number^JXo1X 4Body Text Char#CJOJQJ^J_HhmH sH tH F' AF 4Comment Reference CJ^JaJ8R8 4 Comment Text%CJ@jQR@ 4Comment Subject&5\ZoqZ 4Heading 5 Char&5CJOJQJ^J_HhmH sH tH ^/^ 4Style Comment Reference +CJOJQJ^JaJ8/8 4StyleB*CJ^JaJphbOb 4 Table Heading*$ a$5CJOJQJ\mH sH VOV 4 Table text+$ a$CJOJQJmH sH RR 4 PI - Header 1 ,$a$5;^JaJtH  4 Table Grid7:V-0-$a$_HmH sH tH o 4*(36-46f)(for(pet)11001-minute2202002-8c4550aaddadditionalallowamberanandareatbebeforebenicarbottlecancontainercontainingeachforfourinc.laboratories,leastmgmg/mlminimumminuteminute.minutes.mlofora-plusora-plus*ora-sweetora-sweet*paddockpolyethyle^J:: 4 Footnote Text/CJD& D 4Footnote ReferenceH*^JVV 4000k=1^$CJOJPJ QJaJmH nHsH tHPK![Content_Types].xmlj0Eжr(΢Iw},-j4 wP-t#bΙ{UTU^hd}㨫)*1P' ^W0)T9<l#$yi};~@(Hu* Dנz/0ǰ $ X3aZ,D0j~3߶b~i>3\`?/[G\!-Rk.sԻ..a濭?PK!֧6 _rels/.relsj0 }Q%v/C/}(h"O = C?hv=Ʌ%[xp{۵_Pѣ<1H0ORBdJE4b$q_6LR7`0̞O,En7Lib/SeеPK!kytheme/theme/themeManager.xml M @}w7c(EbˮCAǠҟ7՛K Y, e.|,H,lxɴIsQ}#Ր ֵ+!,^$j=GW)E+& 8PK!Ptheme/theme/theme1.xmlYOo6w toc'vuر-MniP@I}úama[إ4:lЯGRX^6؊>$ !)O^rC$y@/yH*񄴽)޵߻UDb`}"qۋJחX^)I`nEp)liV[]1M<OP6r=zgbIguSebORD۫qu gZo~ٺlAplxpT0+[}`jzAV2Fi@qv֬5\|ʜ̭NleXdsjcs7f W+Ն7`g ȘJj|h(KD- dXiJ؇(x$( :;˹! I_TS 1?E??ZBΪmU/?~xY'y5g&΋/ɋ>GMGeD3Vq%'#q$8K)fw9:ĵ x}rxwr:\TZaG*y8IjbRc|XŻǿI u3KGnD1NIBs RuK>V.EL+M2#'fi ~V vl{u8zH *:(W☕ ~JTe\O*tHGHY}KNP*ݾ˦TѼ9/#A7qZ$*c?qUnwN%Oi4 =3ڗP 1Pm \\9Mؓ2aD];Yt\[x]}Wr|]g- eW )6-rCSj id DЇAΜIqbJ#x꺃 6k#ASh&ʌt(Q%p%m&]caSl=X\P1Mh9MVdDAaVB[݈fJíP|8 քAV^f Hn- "d>znNJ ة>b&2vKyϼD:,AGm\nziÙ.uχYC6OMf3or$5NHT[XF64T,ќM0E)`#5XY`פ;%1U٥m;R>QD DcpU'&LE/pm%]8firS4d 7y\`JnίI R3U~7+׸#m qBiDi*L69mY&iHE=(K&N!V.KeLDĕ{D vEꦚdeNƟe(MN9ߜR6&3(a/DUz<{ˊYȳV)9Z[4^n5!J?Q3eBoCM m<.vpIYfZY_p[=al-Y}Nc͙ŋ4vfavl'SA8|*u{-ߟ0%M07%<ҍPK! ѐ'theme/theme/_rels/themeManager.xml.relsM 0wooӺ&݈Э5 6?$Q ,.aic21h:qm@RN;d`o7gK(M&$R(.1r'JЊT8V"AȻHu}|$b{P8g/]QAsم(#L[PK-![Content_Types].xmlPK-!֧6 +_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!Ptheme/theme/theme1.xmlPK-! ѐ' theme/theme/_rels/themeManager.xml.relsPK] ٻٻX 777:x# %/<=a>EQH I'JK_Vs֥Q(R}Sbehn|#*<Q#t##J$$$%%--..L..../,/[///3464g445<55"=F=o======>/>G>b>>>>6HDHHH I2ItIIIIIGJ\JJJJKbKsKKKQi26aRx͍<mM}ҏ=nؐGv)=ܒ 3_p#l ,QoޠMh̥֡/ʦ$_ϧ &a3Jdɪ AyЫgfz*-R}Scdfgijklmopqrstuvwxyz{}~      !"$+*14:!:t  ,2$u-=[-]HX@L (    c hA ??DBStructure of olmesartan medoxomil3"`?B S  ?H0(  ٻS4 OLE_LINK1 OLE_LINK2 OLE_LINK3 OLE_LINK6 OLE_LINK7 OLE_LINK4 OLE_LINK5R.1.1""ڻZCC!!ڻ'12;[efot{#$-AKLU^hir39o ),anz(Mcov"+S[IST]   -=_i%*3!+~BL`jktZd0: V`u}gq ####''''.(2(((((D,N,O,X,-'-----//G<L<Q<V<========M?R?S?X?????????5@<@>@D@@@@@CCCC;FEFFFOFHHHHHHIIIIJJKKL%L7L;LOOO PUUUUEYTYYYZZiZoZpZzZ]]k^t^_ _BaMaiasata}aaamcucdde(ehhhhhhhipjzj{jjjjj kYkckkkkkl#l$l-lllbnlnnnnnrr~uuuu9yCyzz||||~}}}}9~C~D~M~~~~~ft(6=GDNOX ,AҌ܌݌`jkt͔Δ?J ?IJStӝ=GHQ$6 Y]˥ϥ ILX[ֳ̳(3*.8U]ƺպںPVgnڻQRt )##-$7&&&))*7*e*,B3K3|3344.4<4u4_555<<=====>4>Z?[?r????*@+@'AKAKAHHff.Wmv_%Wpej%KPۛZ {{|gֻڻ zMEQ\ tJhhnt 3~ _n IrC!nQXY'dNv^s-bvQr{.Fn7o1lUr)4xDlIL8Z4iK&*N>T+OZW_lUdd` Da4Rci<|>k")m @oN,PLM p\sUt Lt@l)u ?vĬ}3 M.^J^J^J^J^J^J^J^J hh^h`OJQJo( hh^h`OJQJo( ^`OJQJo( ^`OJ QJ o(o pp^p`OJ QJ o( @ @ ^@ `OJQJo( ^`OJ QJ o(o ^`OJ QJ o( ^`OJQJo( ^`OJ QJ o(o PP^P`OJ QJ o(^`^Jo(.^`^J.pLp^p`L^J.@ @ ^@ `^J.^`^J.L^`L^J.^`^J.^`^J.PLP^P`L^J.^`B*OJQJo(ph ^`OJ QJ o(o pp^p`OJ QJ o( @ @ ^@ `OJQJo( ^`OJ QJ o(o ^`OJ QJ o( ^`OJQJo( ^`OJ QJ o(o PP^P`OJ QJ o( hh^h`OJQJo( hh^h`OJQJo( hh^h`OJQJo( ^`OJQJo( ^`OJ QJ o(o pp^p`OJ QJ o( @ @ ^@ `OJQJo( ^`OJ QJ o(o ^`OJ QJ o( ^`OJQJo( ^`OJ QJ o(o PP^P`OJ QJ o(^`B*OJQJo(ph ^`OJ QJ o(o pp^p`OJ QJ o( @ @ ^@ `OJQJo( ^`OJ QJ o(o ^`OJ QJ o( ^`OJQJo( ^`OJ QJ o(o PP^P`OJ QJ o( hh^h`OJQJo(^`^Jo()^`^J.pLp^p`L^J.@ @ ^@ `^J.^`^J.L^`L^J.^`^J.^`^J.PLP^P`L^J. hh^h`OJQJo( ^`OJ QJ o( ^`OJ QJ o(o pp^p`OJ QJ o( @ @ ^@ `OJQJo( ^`OJ QJ o(o ^`OJ QJ o( ^`OJQJo( ^`OJ QJ o(o PP^P`OJ QJ o(^`B*OJQJo(ph ^`OJ QJ o(o pp^p`OJ QJ o( @ @ ^@ `OJQJo( ^`OJ QJ o(o ^`OJ QJ o( ^`OJQJo( ^`OJ QJ o(o PP^P`OJ QJ o( ^`OJQJo( ^`OJ QJ o(o pp^p`OJ QJ o( @ @ ^@ `OJQJo( ^`OJ QJ o(o ^`OJ QJ o( ^`OJQJo( ^`OJ QJ o(o PP^P`OJ QJ o( hh^h`OJQJo(^`B*OJQJo(ph^`^J.pLp^p`L^J.@ @ ^@ `^J.^`^J.L^`L^J.^`^J.^`^J.PLP^P`L^J. hh^h`OJQJo( hh^h`OJQJo( hh^h`OJQJo( ^`OJQJo( ^`OJ QJ o(o pp^p`OJ QJ o( @ @ ^@ `OJQJo( ^`OJ QJ o(o ^`OJ QJ o( ^`OJQJo( ^`OJ QJ o(o PP^P`OJ QJ o( hh^h`OJQJo(^`B*OJQJo(ph ^`OJ QJ o(o pp^p`OJ QJ o( @ @ ^@ `OJQJo( ^`OJ QJ o(o ^`OJ QJ o( ^`OJQJo( ^`OJ QJ o(o PP^P`OJ QJ o( zz^z`OJQJo( JJ^J`OJ QJ o(o   ^ `OJ QJ o(   ^ `OJQJo( ^`OJ QJ o(o ^`OJ QJ o( ZZ^Z`OJQJo( **^*`OJ QJ o(o ^`OJ QJ o( hh^h`OJQJo(P^`P56CJOJ QJ ^JaJo(. hh^h`OJQJo(^`^J)^`^J.pp^p`^J.@ @ ^@ `^J.^`^J.^`^J.^`^J.^`^J.PP^P`^J. hh^h`OJQJo(#)mnl)uUtdd`Da4RciIQr{.\ +O}3 r)4C!lI z4iKs-3~o1ZW_@ot |>khhLtY'M p*N?vP                   OD                 OD        Pj        OD                 OD                 OD                          "m-_n n 4 En y)|-r <Qb& !?"9#'%F&d,.;/.} /0 .0!\0_4V68)?O@GDC*E'sE;>GuJmLLONO^fQDT= V/XD{X C^o^ g_: b#)d-Rdhd hjmmyxp65qrwRwsk{,}('=,<6J!v $#4BX?y-J.YI!pp.eB*+Y2\[BW+XEe]^v#2V 9 \`k^C]:_:cWJ!=,]+ ,( }SFZ#`D+iwKzr@!L!!89\ٻp@p$pL@pBp@pp@pp@@ppL@pp|@p@UnknownG*Ax Times New Roman5Symbol3. *Cx Arial_Times New Roman BoldTahomaI. ??Arial Unicode MSG@CambriaCambriaG=  jMS Mincho-3 fg5. .[`)Tahoma71 CourierA. Arial Narrow=. jMS PGothic?= *Cx Courier New;WingdingsA$BCambria Math"hjU{2  }o }oq42QHX n 2! xx6Product Information for Olmetec (olmesartan medoxomil) prescription medicine regulation`auspar, prescription, medicine, assessment, regulation, australia, olmetec, olmesartan medoxomil+Merck Sharp & Dohme (Australia) Pty LimitedSheppard, Fran                          CompObjy